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Purpose:  This study was designed to measure the symptom prevalence and symptom 
burden amongst patients attending three HIV treatment clinics in greater Johannesburg, 
and to assess the relationship of these to CD4 count, viral load, WHO stage, functional 
status and HAART.   
Methods:  Patients at the three clinics were invited, using convenience sampling, to 
participate in completing the interviewer administered Memorial Symptom Assessment 
Scale-Short Form (MSAS-SF) which assesses the 7 day prevalence and distress for 28 physical 
symptoms and prevalence and frequency of four psychological symptoms.  Demographic 
and clinical data, including initial and latest CD4 counts, initial and latest viral loads and 
information on HAART use, were collected from the participants and from their clinic files.  
The Karnofsky Performance Status (KPS) scale was used to assess functional status. 
Results:  There were three hundred and eighty five participants with 98% on HAART.  The 
mean symptom number was 10.24 (standard deviation [SD] = 5.7).  The six most prevalent 
symptoms with more than 50% prevalence were:  feeling sad (65%), feeling irritable (62%), 
numbness/tingling in hands & feet (61%), worrying (61%), problems with sexual interest or 
activity (52%) and pain (51%).  The mean distress scores (±SD, range) were:  MSAS-GDI 1.19 
± 0.89 (0-3.84), MSAS-PHYS 0.80 ± 0.71 (0-3.66), MSAS-PSYCH 1.27 ± 1.06 (0-4); and TMSAS 
0.90 ± 0.63 (0.25-3.125).  On regression analysis, KPS scores, WHO stages and the female 
gender were most consistently predictive of the subscale distress scores, while the latest 
CD4 count was only predictive of physical distress and viral load was not predictive of any 
symptom distress. 
Conclusion:   This study shows the high prevalence and high burden of physical symptoms 
amongst patients who attend outpatient HIV treatment clinics, and that this occurs at any 
CD4 count, all WHO stages, and with any KPS score, and among patients who are on HAART, 
motivating for the need for symptom control and palliative care alongside HAART in 













Chapter 1  
Introduction 
The impact of HIV on South Africa and the current situation 
The Human Immunodeficiency Virus (HIV) has significantly impacted on the health status of 
South Africans in general.  The 2010 mid-year population estimate from Statistics South 
Africa is 49.99 million(1).  Gauteng Province, where this study that is being reported was 
conducted, has the largest proportion of the country’s population – 22.4%(1).  For all ages, 
the estimated HIV prevalence is considered to be around 10.5%, while for the age group 
with the highest incidence, those aged 15 – 49 years, the estimated HIV prevalence rate is 
17%(1).  The National Antenatal Sentinel HIV and Syphilis Prevalence Survey in South Africa, 
2009 found the HIV prevalence in 2009 among antenatal clinic attendees aged 20-24 was 
26.6%, for the age 25-29 was 37.1%, and for the age 30-34 was 41.5%(2).  The National HIV 
prevalence study in 2008 showed that for women, the greatest prevalence was for age 
group 25 – 29 years, while for men, the greatest prevalence was for the ages 30 – 34, while 
the prevalence among women remained the highest overall prevalence(3). The estimated 
total number of people living in South Africa with HIV in 2009/2010, was between 5.2 and 
5.63 million(1,2).   
This requires that the question be answered of how many people are in need of HAART in 
South Africa.  The answer to this question also depends on what the national guidelines are 
for starting HAART.  The current guidelines adopted in 2010, are that HAART should be 
started in any patient who has a CD4 count under 350cells/mm³(4).  However, the previous 
guidelines were to start HAART for those patients with a CD4 count under 200cells/mm³(5).  
For 2010, Statistics South Africa estimated that 1.6 million people over the age of 15 years 
would need HAART(1), however it is uncertain whether the 2004 or 2010 guidelines were 
used to calculate this figure, so this number may be significantly higher.  The estimate for 
2009, of the number of HIV positive people over the age of 15 who were actually on HAART, 
is 920 000(1).  There is thus a significant shortfall on the number of South Africans needing 
HAART who are actually receiving it.  This means that many people are starting HAART very 












for dying before starting HAART.  As such, the life expectancy at birth in 2010 for the female 
population is 55.2 years and for the male population is 53.3 years(1).  As a country managing 
a large scale HIV epidemic with these numbers described, we are still trying to catch up to 
meet the HAART needs of all South Africans with HIV. 
 
 
Palliative Care in HIV Treatment clinics in South Africa 
Palliative Care is defined by the WHO as ‘an approach that improves the quality of life of 
patients and their families facing problems associated with life-threatening illness, through 
the prevention and relief of suffering, the early identification and impeccable assessment 
and treatment of pain and other problems, physical, psychosocial and spiritual’(6).  Since 
the advent of antiretrovirals (ARVs) and highly active antiretroviral therapy (HAART), and 
the improved immunological status of patients taking these medications, mortality has 
decreased significantly(7), resulting in the chronicity of the disease as many people know it 
today.  There is a misunderstanding amongst health care workers that patients with such 
chronic HIV disease do not need palliative care.  Palliative care is considered by many to be 
no longer a standard need in HIV treatment clinics in 2011.  However, the WHO definition of 
Palliative Care goes on to say that palliative care “is applicable early in the course of the 
illness, in conjunction with other therapies that are intended to prolong life”, thus 
advocating for applying palliation from the early stages of disease while disease-specific 
management is employed(6).  This is because Palliative Medicine practitioners recognise, 
and the WHO definition affirms, that “relief from suffering” in all its forms and at any time, 
including “pain and other distressing symptoms”, as well as addressing quality of life issues, 
are integral to the management of a patient with a life-threatening illness(6). Symptom 
management therefore should be incorporated together with HAART in the management of 
HIV disease.  Selwyn and Rivard write that “Rather than being ‘either-or’, curative and 
palliative approaches to HIV care need to be ‘both-and’, and one paradigm need never fully 
substitute for the other”(8).  O’Neill and Barini-Garcia confirm this, writing that “Palliative 
Care is complementary care, not alternative care”, motivating for palliation of symptoms to 












There are identified palliative care needs at all stages of HIV disease, with and without the 
use of HAART(10-14).  This was highlighted in a recent correspondence to Clinical Infectious 
Diseases, commenting on the authors’ findings at the recent International AIDS Society 
conference in relation to proposed national and multi-agency human immunodeficiency 
virus (HIV) quality care measures published in Clinical Infectious Diseases(15).  Gwyther, 
from the Hospice Palliative Care Association of South Africa, wrote in a private 
communication that the goal of palliative care for patients with HIV, is the restoration of 
their health as the ultimate goal in the objective of improving their quality of life, and that 
this can be achieved through holistic care which actively addresses the care needs of the 
patient and their family and also necessarily assists in treatment support(16).  A study 
conducted in Uganda, by Wakeham et al, amongst patients with a new diagnosis of HIV, 
found that there is a high prevalence of symptoms amongst patients, even at diagnosis and 
also among patients who are diagnosed in the WHO stage 1 stage of disease, not just among 
patients diagnosed with higher WHO stages of disease(17).  Fontaine et al reported on their 
findings from a multi-centre cross-sectional survey conducted in France, that physicians did 
not reliably recognise the symptoms that their patients experienced and that this was 
particularly low for symptoms that do have treatments (for example nausea and vomiting) 
and for symptoms that may be due to drug side effects(18).  Symptom recognition by 
physicians was best for symptoms which were measurable, such as fever and weight loss; 
and symptom recognition was also better for patients who were perceived to be more ill, 
suggesting that physicians were more vigilant in asking about symptoms in these 
situations(18).  This particular study shows clearly that health care workers should not 
assume symptoms to be absent unless a clear a detailed history has been taken.  It also 
shows that patients are often not able to make their doctors aware of the symptoms from 
which they are suffering, indicating communication gaps.  These issues may in fact call for 
the use of symptom assessment tools in daily clinical practise to improve symptom 
assessment, as part of management protocols for patients with HIV.  This study also speaks 
of the training needs of health care workers around the prevalence of symptoms and how 
burdensome symptoms may be, and also speaks to the training needs around symptom 











This international research is relevant to the South African outpatient HIV treatment clinic, 
but it may be considered to be of theoretical relevance if the prevalence and burden of pain 
and other symptoms are not quantified in these clinic populations.  If we know the symptom 
prevalence and the burden of those symptoms, we will be able to begin to quantify the 
need for, or lack of, symptom management in the South African HIV clinic setting.  This 
study aims to quantify the prevalence and burden of pain and other symptoms in an urban 
clinic setting in South Africa, so that appropriate measures can be taken to address the gaps 
in symptom assessment and management and to motivate for adequate palliative care for 
patients at all stages of disease in outpatient HIV clinics and indeed in other settings of 
health care provision.   
The prevalence of pain and symptoms experienced by patients who are HIV
infected
International research has shown that patients attending HIV treatment clinics often do
have symptoms(10-13).  Most studies that have investigated symptoms amongst HIV 
patients in South Africa, were conducted before HAART was available to patients in the 
government health sector(19-21). These studies showed a high prevalence and burden of
symptoms. However, only one of these studies used a validated symptom assessment
tool(20), so the results are not easily comparable to other South Africa or international
studies.  Since HAART became available, a study carried out in the Eastern Cape points to a 
continued high prevalence of symptoms(22). International studies suggest the continued
high prevalence and burden of pain and other symptoms even with the use of HAART(14,23-
25).  It is not appropriate to extrapolate this international data directly on to the South
African population. In order to adequately assess and manage symptoms amongst a patient
population attending public sector HIV treatment clinics in urban South Africa, we need to
have prevalence and burden data from studies within that population.  Pappas et al(26)
comment that “Estimation of the pain and symptoms in HIV infected groups and in
populations in general will increase our understanding of unmet needs for palliative care.”  
Selwyn writes of the need to ‘reacquaint’ the current medical treatment of HIV, which we 
are now fortunate to have better access to in South Africa (particularly HAART), with what 











care(27).  He writes that we need to “provide our patients with the benefits of both types of 
expertise”(27). 
The quality of life experienced by patients with HIV is complex to measure.  One of the 
measures of quality of life is the prevalence and burden of pain and other symptoms(28-30).  
Other components of the measure of quality of life for patients with HIV may include 
physical function, social function, role function, mental/emotional health, the effect of
treatment and perceptions of the patient’s own health status(28-30). There is indication
from research that symptoms experienced by people with HIV disease are significant in their
impact on overall quality of life assessments, and that HAART does not necessarily resolve 
all symptom problems, although HAART does seem to stabilise quality of life over time(30).  
The relevance of symptoms for the patients who experience them thus go beyond the 
symptom experience in itself, and invade so many aspects of the patients lives, including the 
psychological, social, practical and spiritual dimensions. This confirms the need for clinicians 
and health care workers to understand the symptom prevalence and burden in the patient
population we serve, so as to better understand this part of the influence of the disease on
the quality of life of these patients, and in so doing, be able to treat the treatable symptoms 
to make improvements in patient quality of life.
The burden of pain and symptoms experienced by HIV infected patients
The prevalence of a symptom is of great importance, as it indicates how frequently the 
physician may expect to find the symptom in the patient group served. The presence of a 
symptom is however not enough for a physician to be able to adequately manage the 
symptom for the individual patient. For management of a symptom to be adequate, the 
severity or burden of the symptom needs to be known.  The assessment of management
success requires that the baseline burden of the symptom is known, so as to assess the 
change in the burden of the symptom. The international research described above suggests 
a high degree of burden from those symptoms that have been found to be highly
prevalent(10,14,23-25). This includes psychological symptoms which have been found to be
particularly burdensome to patients, even to those patients who are on HAART(10,14,23-












other Southern African study (pre-HAART), have assessed symptom burden and they have 
found a similar level of symptom burden amongst their study populations as has been found 
internationally(20,22).  Burden from symptoms and psychological distress have been found 
to be correlated to each other and also to functional status and to quality of life 
measures(10).  Of importance is that an increased burden from symptoms has been 
significantly associated with poor HAART adherence(23,31).  Burdensome symptoms that 
are not addressed will therefore cause ongoing suffering and poorer quality of life for 
patients.  The palliative approach aims to specifically address this suffering, so as to improve 
overall quality of life for the patient.   
 
How symptoms and burden from symptom relate to disease-specific 
biological data and to demographic data 
There is international research that suggests that pain and symptoms are prevalent at all 
WHO stages of HIV disease, at all CD4 count levels, and whether patients are on HAART or 
not(10,14,23-25).  This research shows that patients with relatively ‘high’ CD4 counts and 
who are classified as WHO stage 1 or 2, do indeed have significant numbers of symptoms 
and do experience significant burden from those symptoms, and that the prevalence and 
burden of symptoms for these patient groups are not always significantly different to those 
patients with lower CD4 counts and who are staged as WHO stage 3 or 4 disease(10,14,23-
25).  This research is important for health care workers to be aware of and points to the 
importance of assessing each patient as an individual and to being patient-focussed, rather 
than being disease- and/or virus-focussed.  There is very little data on these important 
aspects of HIV patient management recorded in an urban South African HIV treatment clinic 
context.  Research that was done in South Africa before HAART became available, did not 
evaluate the relationship between symptoms and burden from symptom, with CD4 counts, 
viral loads, performance status, gender or age(19,20).  Since the availability of HAART in the 
government health service, two studies have been conducted that assessed the presence of 
symptoms and that have, to varying degrees, compared these to biological and 
demographic data(22,32).  One of these studies was conducted in a rural population(22) 
while the other does not make it clear whether it was an urban, rural or mixed 












error(22), while the other study, using clinic records for accurate CD4 count collection, did 
not relate symptoms to any of the biological or demographic data, but compared a broader 
assessment of quality of life to some of these variables(32).  We therefore know that 
symptoms could be expected to be prevalent in the urban study population proposed for 
this study, however the symptom prevalence and burden has not been formally researched 
in this environment and extrapolations from other population groups are unwise.   
Without knowledge of what to expect of patient symptomatology, the health care worker’s 
index of suspicion for symptoms may be low.   Patients who do not feel able to voice their 
needs and who are not given a real chance and permission to do this, will not address their 
symptom problems with their health care worker.  Such vulnerable people are those that 
receive care from the government HIV treatment clinics in South Africa.  This means that 
patients who are on HAART, regardless of CD4 count, or patients receiving pre-HAART 
treatment at HIV treatment clinics may not be adequately screened for symptoms and 
burden from symptoms and there may be inadequate or absent symptom assessment and 
management for patients.  Without knowledge of symptom prevalence and burden and how 
these occur at different WHO stages and CD4 count levels, health care providers may be 
unaware of their own training needs in the areas of symptom control and palliation for the 
patients they see everyday in the HIV clinic setting.  
 
Management of health-related symptoms for HIV infected patients 
Without recent data in the era of HAART on the pain and symptom prevalence and burden 
amongst HIV infected patients in South Africa, we are not able to comment on the need for 
or the adequacy of the symptomatic management of patients attending HIV treatment 
clinics.  International studies have suggested that pain and other symptoms are 
undertreated(13,33,34).  Palliative care is patient-focused, attending to the individual needs 
of individual patients.  South African HIV treatment clinics tend to be very busy, with many 
patients requiring review each day.  The focus is on immunological, virological and clinical 
disease control.  This is often life-saving treatment for patients.  The accompanying 
questions relating to quality of life issues, are however, often considered to be of secondary 











some of these needs may be and in so doing, why these needs may actually not be of 
secondary importance.  It is also of importance to point out that a recent study of the 
availability of analgesia and related medication in Sub-Saharan Africa (including South 
Africa) for patients with palliative care needs, including HIV patients, showed a marked 
discrepancy between ideal analgesic, antiemetic and anxiolytic availability and actual 
availability(35).   This highlights the lack of understanding of pain and symptom control 
needs at national and local levels.  An interventional study by Green et al, which used a non-
randomised control trial method, with an embedded qualitative study, was begun in 
northern Vietnam in 2007 to assess the effectiveness of introducing palliative care into 
existing HIV outpatient treatment clinic services(36).  The reported preliminary findings have 
shown that at baseline only 5% of the symptoms experienced by patients were documented 
by the clinicians, while after a symptom assessment tool was introduced as part of the clinic 
service protocol, with clinicians trained in pain and symptom management, 98% of patients 
had documented symptom assessment for at least one visit, and 93% of patients had 
symptoms documented more often(36).  There has also been improved symptom 
management for patients with neuropathic pain and with depression, and very importantly, 
the qualitative part of the study showed that clinicians were very pleased at being able to 
assess and manage their patients’ symptoms(36).  This study shows that integration of 
palliative care assessment and management strategies into regular HIV outpatient 
treatment clinics in a developing country is possible and indeed very necessary for the 
holistic management of patients with HIV, and that palliative care does indeed improve 
patient outcomes. 
Symptoms and Adherence to HAART 
Research indicates that there is significant evidence that symptoms and the burden of 
symptoms experienced by patients, affect HAART adherence directly and indirectly, as well 
as independently affecting virological disease control(31,37).  This is of great importance for 
the South African HIV infected patient, where stigma and poor education, among other 
factors, still continue to dominate the decisions of patients requiring HAART.  It has been 
shown that pain, other physical symptoms and also psychological symptoms, especially 












Another interesting finding by Sherr et al was that patients who had greater satisfaction 
with their doctor-patient relationship, had better HAART adherence than those who 
reported less satisfaction with their doctor-patient relationship(31).  A good doctor-patient 
relationship is likely to be one in which symptoms are readily discussed and effectively 
managed.  This research proves that it is crucial to know how and why patients with HIV in 
South Africa suffer, so as to manage them effectively and holistically, in an attempt to 
maintain HAART adherence for maintained virological suppression and HAART treatment 
success.   
 
Summary 
This study was conducted at three adult HIV treatment clinics in Johannesburg, South Africa.  
The clinics are at three academic hospitals attached to the University of the Witwatersrand’s 
Medical School, namely the Charlotte Maxeke Johannesburg Academic Hospital, the Chris 
Hani Baragwanath Hospital and the Helen Joseph Hospital.  At these clinics, as in the 
majority of other HIV treatment clinics in South Africa, anecdotal evidence is that HIV 
management has been provided, predominantly in the form of HAART and disease-centred 
management, with minimal symptom assessment and management in a patient-centred 
manner.  
The following issues are not adequately addressed by current research:  the prevalence of 
pain and symptoms and the burden imposed by these symptoms as experienced by urban 
South Africans who attend HIV treatment outpatient clinics; the relationship that symptom 
prevalence and burden may have with CD4 counts, viral loads, WHO stage of disease, 
functional status and HAART.  Prior research in other settings indicates that these are 
important aspects of the HIV disease experience to understand, so as to manage patients 
more effectively, in conjunction with HAART.  It is the intention of this study to document 
the symptom prevalence and the burden of these symptoms that are experienced by the 
patients attending HIV treatment clinics in the urban setting of greater Johannesburg, and 
to analyse the relationships that may exist between the symptoms and the burden of 
symptoms with the variables highlighted.  In this dissertation, I describe the study 












outline and discuss the current literature on these issues, expanding on the issues raised 
thus far.  In chapter three the aims and objectives of the study are stated and in chapter 
four the details of the study methods are described.  The results of the study are described 
in chapter five.  In chapter six the results are discussed and the findings are concluded in 




















This literature review was compiled by searching MEDLINE databases through Pubmed,
Ebsco and Ovid, and also using Google Scholar to extend searches. Particular references 
that were found through reading relevant journal articles and book chapters, were also
specifically searched for through the MEDLINE database. This literature search was done 
over a period of time from the period of protocol development, during the time of data 
collection and completed during the write up of the findings in this dissertation. The words 
used for the searches (and used in combination) include: palliative care, HIV, symptoms,
pain, depression, symptom assessment tools, symptom assessment, symptom burden, 
symptom distress, symptom experience, HAART, ART, quality of life, adherence, function, 
prognosis, antiretrovirals, AIDS, prevalence, outcome and review. All literature reviewed
related to an adult study population. 
South African and Southern African studies on symptoms experienced by
HIV positive people
There are relatively few studies done in South Africa amongst HIV infected adults that have
specifically looked at the symptom prevalence and burden in HIV positive people, 
particularly since HAART became available in the state health service. Symptoms are
defined as “any subjective evidence of disease or of a patient’s condition, i.e. such evidence
as perceived by the patient”(39).  Symptom prevalence is defined as “the numbers of cases 
of (symptoms) that are present in a population at a specified time”(39).  For the purposes of
this study, and in the writing of this dissertation, prevalence refers to “point prevalence” 
which is prevalence “at a point in time”(39). Symptom burden refers to the physical burden 











Norval studied the most prevalent symptoms and most common sites of pain in a cross-
sectional descriptive study, in a hospice-based population in Soweto in 2002-2003, before 
HAART was available to patients in the state health sector(19).  The study population 
included all the registered adult hospice patients at the time of study who were willing to 
participate and who fulfilled the selection criteria, reaching a reasonable study sample 
size(19).  Patients all had advanced AIDS, WHO stage 4 disease and the group was 
predominantly female(19).  The most prevalent symptom was pain, for 98% of participants, 
and 34.4% of participants identified pain as their worst symptom, with an average of 2.91 
pains per patient, while the other most common symptoms identified were typical of 
advanced life-threatening disease, included weight loss, loss of appetite, low mood, 
weakness and fatigue(19).  The burden of each symptom was not directly assessed and the 
symptom assessment tool was not a validated tool, however this study highlights the 
significant symptom prevalence amongst people who have advanced AIDS and who are 
dying of AIDS, and have for the most part not had the benefit of HAART.  The mean number 
of pains in this study is similar to that found by a study in the USA which found an average 
of 2.7 pains per patient(12).   
In a cross-sectional descriptive Southern Africa study done by Makoae et al in 2002, the
frequency and intensity of symptoms amongst HIV positive people in South Africa, 
Botswana, Lesotho and Swaziland was assessed(20). This was a multi-centred study with a 
good sample size, including a mix of participants from urban, peri-urban and rural areas(20). 
In this study, no ART use was reported by participants and there was generally little 
availability of these drugs. The validated 64-item Revised Sign and Symptom Checklist for 
Persons with HIV disease was used to assess for symptom prevalence and intensity, 
reporting a mean total number of symptoms of 17.58 per person, with the top five 
symptoms not unlike those found by Norval, being fatigue, weakness, concern over weight
loss, fear and worries, and painful joints(19,20). This is a valid study which achieved its 
objectives and found significant psychological distress on the 3 point Likert scale, and also
showed a significant relationship between symptom frequency and a) financial problems
and b) the presence of children to care for(20) .
A more recent cross-sectional study using convenience sampling, conducted by Peltzer and 












assessment tool as Makoae et al, found a symptom prevalence of 26.1 symptoms per 
person(22).  In this study of good sample size, 48% of participants were on HAART and the 
most common symptoms found on the day of study were not unlike the symptoms found by 
Makoae et al and Norval, but specifically highlighted the issue of fatigue amongst their study 
sample(19,20,22).  The data for this study was acquired by interviewing the participants and 
using their recall for clinical data, rather than clinic files, which is open to bias(22).  
Participants on HAART were found to experience more numbness or tingling of hands or 
fingers than those not on HAART and overall this study found that HAART was not 
associated with a decrease in symptom burden and in general a significant number of 
psychological symptoms were found(22).  It appears that the majority of the aims of this 
study were achieved. 
A longitudinal study of rather limited sample size, conducted by Bhargava and Booysen in 
the Free State Province of South Africa in 2004, at the beginning of the availability of HAART 
in South Africa, did not directly report on symptom prevalence and burden, but showed that 
patients who felt that they received emotional support had a significantly greater increase 
in CD4 cell counts following HAART initiation as well as better quality of life scores than, 
than patients who did not feel they received emotional support(32).  The same study found 
that better perceived health care services resulted in better CD4 count improvements; and 
that better health care worker ratings and higher CD4 counts were related to improved 
quality of life in patients(32).  The finding that the perception of better heath care service 
was related to better quality of life for patients shows that the quality of the health care 
service that is provided does appear to impact on patient outcomes(32).  The findings from 
a United Kingdom study by Sherr et al which will be discussed in more detail further on in 
this chapter, clearly showed that better relationships with clear and equal communication 
between the patient and the health care worker result in better HAART adherence(31) and 
they give the findings of Bhargava and Booysen particular credence and are of importance 














African studies on symptoms experienced by HIV positive people 
An attempt was made to access the relevant studies conducted in Africa, and it appears that 
studies in this particular area of symptom prevalence, tend to be conducted in Uganda, 
Malawi, Botswana, Lesotho and Swaziland(17,20,40).  An audit carried out in 2003 and 2004 
over an 18 month period in Malawi by Bowie et al, was done in their pre-HAART era, in a 
home-based care patient group of whom 70% of patients were clinically diagnosed as WHO 
stage 4 disease(40).  Records of initial and follow up patient assessment and management 
notes were audited(40).  Pains were recorded by site, with 84% of participants experiencing 
moderate to severe pain at initial assessment visit, and with headache, fever, chest pain, 
shortness of breath and cough as the most prevalent symptoms(40).  The functional 
capacity of the sample was poor, with only 44% of participants being able to care for 
themselves(40).  This audit of a good number of patients is useful for recording the 
symptom prevalence over a period of time in end-stage HIV disease before HAART became 
available, but did not use a validated symptom assessment tool and therefore may even 
have under-reported on symptoms and also did not report on symptom burden. 
The study by Wakeham et al in rural Uganda assessed symptom prevalence and burden, at 
the time of HIV diagnosis, to assess whether WHO staging and or CD4 count had any impact 
on symptom prevalence and burden(17).  Participants of a particular double blind 
randomised placebo controlled trial were all invited to participate in this associated study 
on symptoms(17) and good participant numbers were attained.  The validated Memorial 
Symptom Assessment Scale - Short Form (MSAS-SF) was used, and an additional 9 
symptoms were added to the original 32 symptoms of the MSAS-SF(17).  The sample was 
59% female, and 62% of participants were in WHO stage 3 and 6% WHO stage 4(17).  The 
mean total number of symptoms was 14 with the top 6 physical symptoms being pain, 
weight loss, itching, feeling drowsy/feeling tired, lack of energy, numbness or tingling of 
hands or feet and the two most common psychological symptoms were worry and feeling 
sad(17). These psychological symptoms were highly frequent if present(17).  This study 
assessed the relationship of symptoms to biological and demographic factors and found that 
the number of symptoms increased for increasing disease stage by WHO staging, but even 
participants who were staged WHO stage 1 had a median of 9 symptoms, and 63% of these 












slightly more symptoms than those with CD4 counts ranging from 100-200, and so there 
was no statistically significant difference in symptom prevalence and burden between these 
CD4 count groups(17).  This is an important piece of research which attained their study 
aims and could show that for patients who are newly diagnosed with HIV, symptoms can 
and do occur at any stage of HIV disease, and at any CD4 count.  However, it may not be 
correct to extrapolate these results onto patients who have already had an HIV diagnosis 
previously and are further along the disease trajectory.   
 
International studies on symptoms experienced by HIV positive people 
Far more study on symptom prevalence and burden has been done internationally, than in 
South Africa.  The studies described below, show significant symptom prevalence and 
burden, both in the physical and psychological symptom groups.   
In New York City, Vogl and colleagues conducted a large cross-sectional survey between 
1992 and 1995(10).  Participants were all diagnosed with AIDS (CD4 count <200, or CDC 
clinical category 3) and were attending an outpatient clinic(10).  The researchers used the 
validated MSAS-SF to gather information regarding symptom prevalence and burden, and 
also the Karnofsky Performance Status Scale, the Brief Symptom Inventory, the Beck 
Depression Inventory, the Beck Hopelessness Scale, the Functional living Index – Cancer 
(modified for AIDS), and the Social Support Questionnaire – Short Form, thus using a 
comprehensive array of tools to assess the patient experience of disease(10).  The mean 
number of symptoms per person was 16.7, out of a possible 32 MSAS-SF symptoms(10).  
Twelve symptoms had a prevalence of over 60%, namely worrying, lack of energy, feeling 
sad, pain, feeling irritable, difficulty in sleeping, feeling nervous, dry mouth, difficulty 
concentrating, shortness of breath, feeling drowsy and cough, showing a high prevalence of 
psychological symptoms and symptoms related to the psychological distress subscale(10).  
This study found no relationship between CD4 count and symptom prevalence or distress or 
any of the other MSAS-SF measures, but the authors felt this could be studied further, and 
that viral load results may be useful(10).  The study methods employed were 












Silverberg et al studied the prevalence of symptoms amongst women, in relation to HAART, 
as part of the multi-centre prospective cohort Women’s Interagency HIV Study (WIHS) in the 
USA which included a control group of HIV negative women(11).  Symptoms were assessed 
using an apparently non-validated questionnaire between October 1999 and April 2003(11).  
The most prevalent symptom was fatigue, then headaches and myalgias and the study 
found that the women with the highest number of symptoms were in the groups who had 
stopped all ART and in those who had ever changed HAART regimens(11).  In their control 
group, women who were HIV negative did have symptoms, but had far fewer symptoms 
than HIV positive women(11).  This study did not specify a symptom assessment tool used 
and did not make clear which symptoms were assessed for, making it difficult to compare 
with other studies.   
In a cross-sectional online survey among gay HIV positive men in the United Kingdom, in 
2004, Harding et al found a mean number of 12.3 symptoms (out of a possible 32 symptoms 
on the MSAS-SF), but that those men on HAART had more symptoms (14.0) than those not 
on HAART(10.3)(24).  The sampling method used may have introduced selection bias, but 
the study population was found to be reasonably similar to samples from community 
sampling(24).  The most prevalent symptoms were worrying, feeling sad, feeling irritable, 
lack of energy, feeling nervous, difficulty in sleeping, difficulty in concentrating, feeling 
drowsy, problems with sexual interest or activity, diarrhoea and pain, which is similar to the 
findings in the study in New York by Vogl et al, particularly for the frequency of 
psychological symptoms(10,24).  The most prevalent overall symptoms were psychological 
symptoms, but certain physical symptoms were more prevalent amongst those on 
HAART(24).  In contrast to Vogl et al, they found that the latest CD4 count had a very weak 
but significant relationship with global distress scores(10,24).  The use of a validated 
symptom assessment tool that has been used in recent HIV symptom research, with 
appropriate analysis of symptoms in relation to biological and demographic data, despite 
being self-reported by the patient and only among gay men sampled online, makes this a 
useful study. 
Willard et al reported on a secondary analysis of two international multi-site studies on 
symptom prevalence and intensity in HIV disease, each of large sample size, and concluded 












experience and severity, and that those patients with CD4 counts over 350, regardless of 
HAART use, are not less symptomatic than those with lower CD4 counts(14).  The one study 
reviewed was cross-sectional, and the other study was a randomised controlled trial where 
only the baseline data was used, meaning that the level of evidence reviewed was 
appropriately significant, and the validated Revised Sign and Symptom Checklist for Persons 
with HIV Disease (SCC-HIVrev) symptom assessment tool was used(14).   
A cross-sectional multi-centre study, conducted in London in 2005-2006, by Harding and 
colleagues, of a large sample size of consecutively approached AIDS outpatients, with 67.4% 
of patients on HAART at the time of the study, found a high rate of burden of psychological 
symptoms and of pain(23).  Participants completed their own questionnaires of clinical and 
behavioural data and also the MSAS-SF(23).  Lack of energy was the most prevalent 
symptom at 70.8%, with the following most prevalent symptoms being feeling drowsy, 
difficulty sleeping, difficulty concentrating, diarrhoea, problems with sexual interest or 
activity, pain(23).  The psychological symptoms were very common, with worrying being 
most prevalent, then feeling sad(23).  HAART was not linked to a change in symptom 
prevalence, while poorer HAART adherence was related to psychological and global distress, 
and patients who had ever changed HAART had more symptoms and increased physical, 
psychological and global distress(23), similar to the findings of Silverberg et al(11).  This 
study achieved its study aims, making it useful and valid. 
A longitudinal study conducted in the USA, by Karus and colleagues, of good sample size, at 
three different HIV patient palliative care sites (Alabama, Baltimore and New York City), 
reported patient symptoms at first assessment, and found a high prevalence of physical and 
psychological symptoms, using the Memorial Symptom Assessment Scale (MSAS) with two 
modifications(34).  The most common symptoms were lack of energy, pain, worrying and 
difficulty sleeping(34), which were similar to the findings of other studies(10,23,24).  The 
average number of symptoms per site was 12.7, 11.9 and 10.9 and these and differences 
noted between the sites highlighted the need for studies to identify the specific needs of 
specific patient populations(34).  Inadequate information of patient use of HAART was 
provided, making comparisons with other surveys and interpretation of the relevance of the 











Studies focusing on Pain  
Pain has been defined by the International Association for the Study of Pain (IASP) as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage”(41).  Pain is moderated by the patient’s 
mood, morale and the meaning of the pain for the patient(42).   
As far as pain itself is concerned, there are a number of studies that have addressed the
issue of pain in HIV(12,13,33,43-46).  Breitbart el al found that in the sample of AIDS
outpatients in a study on the treatment of pain in New York, in the USA, that the prevalence 
of pain that was ‘frequent or persistent’, was over 60%, with a mean of 2.5 distinct
pains(43). Rosenfeld et al who wrote a follow-on article to Breitbart et al, on the same
study, noted that there was a definite correlation between pain and emotional distress, 
depression, loss of hope and quality of life factors(44). A further survey of the patient
population described by Breitbart et al, was conducted by Hewitt et al, to research the pain
syndromes and their causes amongst AIDS outpatients in N w York, in the USA(12). In this 
survey which was of reasonable sample size, 61% of patients, of whom most were
diagnosed with AIDS, had frequent or persistent pain(12). The mean number of pains each
patient experienced in the past week was 2.7(12). Patients were clinically examined for 
aetiology and the breakdown according to pain type showed that 71% of the sample had
one or more somatic pains, 46% had neuropathic type pain, 29% with visceral pains, and
46% experienced headaches(12). Patients who had lower CD4 counts were more likely to
have a polyneuropathy and headache, and women also were more likely to have headaches
than men, according to logistic regression analysis(12). Five percent of somatic pain, 5% of
visceral pain and 3% of neuropathic type pain appeared to be due to treatment for 
HIV/AIDS(12). 
Breitbart et al studied the undertreatment of pain in the same patient population described 
for the study by Hewitt et al above, with a sample size of 366 participants, of whom 48.7% 
reported their worst pain to be between 8 and 10 out of 10 (which is severe pain) and 45.6% 
of patients had moderate pain (4 - 7 out of10)(33).  On average, 60% of patients had 
complete pain relief, while only 18.1% of patients with moderate pain and only 7.3% of 
patients with severe pain, had had opioids correctly prescribed(33).  Forty eight percent of 












been prescribed no analgesia at all(33).  According to WHO analgesic management 
guidelines, 84.1% of all the patients had Pain Management Index (PMI) Scores indicting 
inadequate analgesic treatment (namely a PMI of 0 and above), while using a more 
conservative cut off measure for the PMI (only patients with a PMI of -2 or -3), 49.1% of 
patients had inadequate analgesia(33).  This shows significant under-treatment of pain.  
Risks for inadequate analgesic treatment were the female gender, lower levels of education, 
having acquired HIV through injection drug use(33).  Despite the limitations of the study 
cited by the authors, this study highlights the general undertreatment of pain amongst the 
HIV positive outpatients.  The reasons for this undertreatment are proposed as being due to 
lack of physician knowledge of pain management, the stigma of HIV disease, as well as 
patient related factors(33).  These studies all highlight the prevalence of pain as well as its 
under-treatment.  It is not known what the adequacy of treatment of pain is in the South 
African HIV outpatient setting as no formal study in this area has been done, but clinical 
work in the field suggests that pain is not adequately treated in HIV outpatient clinics, and 
the reasons may be similar to those cited by Breitbart and colleagues.  As yet unpublished 
findings, according to a study conducted at a community HIV treatment clinic, by Parker in 
Cape Town among women with HIV, provide evidence for pain being markedly undertreated 
in this setting(47).  The mean PMI score was -1.3, indicating inadequate analgesia(47).   Only 
two patients out of 229 were found to have adequate analgesia(47).  These findings support 
the perception that pain management is far from adequate at the level of primary HIV care. 
In a longitudinal study of reasonable sample size in Copenhagen, Denmark, in 1994, Frich et 
al found, using semi-structured interviews, that 88% of AIDS patients experienced some 
form of pain at some time during the study, 69% had constant pain which interfered 
significantly with their function, and the prevalence of disturbing pain was 51%(13).  Those 
patients with disturbing pain had shorter mean survival time in days than those with no pain 
or non-disturbing pain(13).  At the time of the study, there was some advancement in anti-
retroviral therapies (ART), and so 50% of patients had some form of ART, whether 
monotherapy or combined therapy(13).  This study achieved its objectives, but did not 
adjust the PMI for adjuvant analgesic use(13). It is important in highlighting the importance 
of pain management in alleviating suffering at the end of life, and possibly also to show how 












Richardson et al studied the pain experience among a good sample size of women with AIDS 
between 1996 and 1998 as part of the Women’s Interagency Health Study, by the use of an 
interview using recall for a 6 month period which may have introduced recall bias, but they 
found that 56% of the women had pain on 6 or more days in the preceding 6 months, and 
that CD4 counts under 200 cells/mm³ and depressive symptoms were associated with 
increased pain frequency and severity(45).  Despite the limitations of this study, it highlights 
the importance of pain assessment and management and the potential relationship 
between pain and psychological well-being for women with AIDS. 
Del Borgo et al found that using the validated Italian Pain Questionnaire (IPQ, Italian version 
of the McGill Pain Questionnaire), the prevalence of pain in their Italian patient sample, of 
whom 34% were on ART, was 60.8%(46).  The most common site of pain was in the 
head(46).  Patient staged CDC C had 60% prevalence of pain, with the group CDC A and B 
having 61% pain prevalence, showing that pain occurs at any stage of HIV disease(46).  The 
sample size was reasonable and consisted of a cross-sectional group of patients admitted to 
the wards or to the Day Treatment Centre of one hospital in Rome and the study aims 
appeared to have been reached, using the pain the IPQ and a clinical examination of each 
patient(46).   
In their article describing ‘The Charter Study’, a cross-sectional study using multiple 
assessment measures, Ellis et al write that HIV-associated sensory neuropathy and 
neuropathic pain continue to be problematic for patients, despite HAART, and they suggest 
that from their study results, preventing the CD4 count from going below 350, with HAART, 
could be protective against developing a sensory neuropathy and hence also neuropathic 
pain(48).   In their study, the prevalence of HIV-associated sensory neuropathy was 57.2%, 
with 38% of these patients having neuropathic pain(46).  The study was conducted at six 
academic outpatient research centres in the USA, with a very large sample size and with 
each participant undergoing a structured interview, a standardised examination, collection 
of demographic and clinical data, including blood tests, and evaluation of function, 
psychiatric state, and quality of life(46).  It is not clear in the article whether the clinician or 
the patient rated the severity of the pain, however the results of this study are relevant to 












All these studies do point to a high degree of physical and psychological symptom 
prevalence and burden amongst people living with HIV who attend HIV outpatient 
treatment clinics.  The international studies highlight the lack of specific evidence in the 
South African setting, for pain and symptom prevalence and burden.    
 
The relevance of Palliative Care to HIV disease management 
The definition of Palliative Care was discussed in the Introduction.  The importance of 
palliative care for patients at all stages of HIV disease was discussed, because as the WHO 
definition states, palliative care is “is applicable early in the course of the illness, in 
conjunction with other therapies that are intended to prolong life”(6).  Supporting this is the 
evidence from international research amongst HIV infected populations showing that 
symptoms are frequent among patients of all WHO stages of disease, including in WHO 
stage 1 disease(10-14).  The research confirms the need for palliative interventions to be 
available for HIV infected patients at all stages of disease and “in conjunction with other 
therapies that are intended to prolong life”(6) which refers specifically to HAART in the 
instance of HIV disease.  Extension of life without reasonable efforts to also address the 
patient’s quality of life is not ethically justifiable, and as such palliative care aims to 
“enhance quality of life, and may also positively influence the course of illness” by using “a 
team approach to address the needs of patients and their families” and to provide 
treatment for the “relief from pain and other distressing symptoms”(6).  This strongly 
suggests that palliative care for patients with HIV should be a part of and integrated with 
their ongoing HIV medical care from early on in the disease. 
A study conducted in New York in 2000 and 2001, by Selwyn et al, using the validated MSAS, 
showed that the palliative care needs of HIV infected patients in the era of HAART-induced 
chronic HIV disease are becoming increasingly complex and therefore no less important 
than before, particularly for end-stage HIV disease in this setting(49).  The article aptly 
describes what it set out to describe, namely the development of an integrated palliative 
care service for patients with AIDS who were cared for at a large hospital with inpatient and 












patients with end-stage HIV disease, but also recognising the increased complexity of 
palliative needs that are required as patients survive longer in the era of HAART(49). 
The benefit that patients with HIV experience from palliation has been explored in the 
literature(49,50).  In a systematic review conducted by Harding and colleagues, they found 
evidence from studies of grade 3 level evidence, to suggest that for patients with HIV and 
AIDS, palliative care carried out in the home and in inpatient hospice units did significantly 
have a positive effect on the patient pain and symptom experience(50).  Despite finding 
predominantly grade 3 level evidence for palliative care, this review further stated that the 
evidence points to a significant symptom burden at all stages of HIV disease, and that 
palliative management is therefore warranted and required alongside the successes of 
HAART at prolonging life(50).  It was also stressed that despite the success of HAART, there 
are the ongoing issues of a serious, chronic and potentially life-threatening disease to deal 
with – including the potential for the development of malignancies, drug toxicities and 
failure on HAART(50).  To add to the evidence that HAART does not necessarily decrease 
symptom prevalence, is a subsequent study in the United Kingdom by Harding et al, which 
found that gay men on HAART had a greater symptom prevalence and greater distress from 
physical symptoms than those HIV positive gay men not on HAART(24).  The evidence 
strongly points to the continued need for palliative care for patients with HIV, regardless of 
what stage of disease the patient is classified as, or what treatment the patient receives.  
 
The relationship between clinical parameters and symptom prevalence and 
the burden of symptoms 
There have been a number of studies attempting to link clinical parameters to symptom 
prevalence and burden, and there have been varying results reported.  The CD4 count and 
viral load markers are obvious and frequently checked markers in HIV disease management.  
The staging methods for HIV disease, both WHO staging and CDC staging, have also been 
studied for their relationship with symptoms(10,17,25,46).  Holzemer writes that the link 
between symptoms and biological markers of disease progression is not well defined(51).   
Some important studies have found no relationship between symptom prevalence and 











polyneuropathy could be linked to a lower CD4 count(12).  Harding et al reported a very 
weak but statistically significant relationship between the most recent CD4 count and the 
global distress rating on the MSAS-SF(24), while Lee et al found that patients with a CD4 
count of less than 200 had higher physical distress scores on the MSAS-SF(25). Richardson et 
al found in univariate analyisis that a CD4 count of less than 200 was significantly associated 
with an increased pain frequency and severity, and a viral load over 50 000 was related to 
higher pain frequencies, in their sample of HIV positive women, although in the multivariate 
analysis of this study, only pain severity could be significantly related to CD4 count(45).   
The Charter Study found on multivariate analysis that there was a relationship between the
presence of HIV sensory neuropathy (but not neuropathic pain) and a lower lowest ever CD4 
count result (<350cells/mm³), whereas neuropathic pain was related to a higher lowest ever
CD4 count and better CD4 count recovery(48). This shows the complexity of HIV 
neuropathy and neuropathic pain. The Charter Study found no relationship between viral 
load measurements and sensory neuropathy or pain(48).
A study by Ickovics et al, analysing the relationship between death, CD4 counts and
depressive symptoms in women found that women with symptoms of chronic depression
were more likely to have a larger decrease in CD4 count than those without such symptoms,
that lower CD4 counts were correlated with greater numbers of depressive symptoms and
that death was more likely in those with more HIV-related symptoms(52). Lampe et al
found in their study in an HIV outpatient clinic in London that patients with symptoms of
depression, anxiety and other physical symptoms were at risk for virological failure on
HAART and that this was considered for the most part to be independent of a lack of
adherence to HAART(37).  On regression analysis of their data of a sample of which 71% of
participants were on HAART, Lee et al found that the viral load was a marker for a change in
symptom prevalence(25). There are a number of studies that have found a change in 
relationship between symptom prevalence and burden with AIDS-defining diagnoses or
WHO staging(10,17,25), whereas, Del Borgo et al reported similar prevalence rates for pain
in all three CDC categories(46).  
The results from these various studies indicate that symptom prevalence and burden and 












any stage and viral load at any stage, are not straight forward by any means.  Some studies 
show an increasing symptom number with worsening disease stage(10,17,25), and some 
show no link between CD4 count levels and symptom number(10,14,17).  Distress or burden 
from symptoms is less clearly related to disease stage, CD4 counts and viral loads.  Different 
study methods and sample characteristics make comparisons between studies difficult.  
What does seem to be clear is that patients can be symptomatic from their HIV disease at 
any point in the disease process, and therefore, as Willard et al comment, the term 
“asymptomatic” should not be casually applied to any patient with HIV, unless the clinician 
has thoroughly checked that this is in fact the case(14).  What is also interesting is that a 
study in New York found that there was no predictive value for death from CD4 counts or 
from viral loads, while functional status, as measured by the Karnofsky Performance Status, 
Mini-Mental State Examination and changes in activities of daily living, were predictive of 
death(49).  This evidence further points to the notion of an individualised and patient-
oriented assessment, rather than relying on “the numbers” of the CD4 counts and viral loads 
to be predictive of suffering from symptoms and even predictive of death. 
 
The relationship between gender and age with symptom prevalence and 
the burden of symptoms in HIV disease 
Statistics in South Africa show that women have a higher HIV infection prevalence than 
men, as was discussed in the introduction.  The 2010 HIV prevalence estimates for women 
aged 15 to 49 years of age, is 19.7%, whereas the overall prevalence for the population of 
this age is 17.3%(1).  Some studies of symptom prevalence and burden have commented 
that women tend to have greater symptom prevalence(25) and some studies have found 
this for specific symptoms, such as anxiety(19), genital problems(19), headache(12) and 
features of radiculopathy(12).  Breitbart et al found that women with pain had a greater 
likelihood of having inadequately treated pain than men(33).  The relationship between 
gender and symptom prevalence and burden is thus not clearly defined in the literature.  
Causality can not be determined from cross-sectional studies, and the variables at play are 
vast and could include social factors, financial factors, educational factors, and factors 












Not much work has been done on the influence of age on symptom prevalence and burden 
of symptoms in HIV disease.  One study by Sherr et al found some differences between the 
two age groups of older than or younger than 50 years, with those older than 50 years of 
age having lower psychological and global distress scores than patients younger than 50 
years of age, while the physical scores were no different(53).  They also found that those 
older than 50 were more likely to be on HAART and were more likely to be adherent to 
HAART than the younger group(53).  This is different to a study conducted in the Free State 
Province in South Africa found that older patients had worse CD4 count outcomes than 
younger patients, however, this study was small, and the CD4 count measure was not 
directly related to symptom prevalence(32).  No conclusions can be drawn from the 
literature on the influence that age has on symptom prevalence and burden. 
 
The relationship between Highly Active Anti-Retroviral Therapy (HAART) 
and symptoms prevalence and the burden of symptoms 
Highly Active Antiretroviral Therapy (HAART) has become the standard management for HIV 
disease once CD4 counts reach a certain level or when disease progression includes an AIDS-
defining condition.  The use of HAART as apposed to dual-therapy or mono-therapy regimes 
has been shown to have the best virological, immunological and clinical outcomes for HIV 
management(54).  The acceptable CD4 count cut-off level at which to start HAART, has 
changed over the years and has varied from country to country and by place of care.  The 
effectiveness of HAART in its ability to improve immunological status and function and to 
suppress the HIV viral load is widely accepted(7), providing it is used in the recognised 
manner.  What often happens in a busy HIV outpatient clinic is that the markers of the 
effectiveness of HAART (disease-focused markers, such as CD4 counts and viral loads) 
receive attention, rather than the patient-focused markers of disease, such as symptoms 
and the burden of those symptoms.  This results in the neglect of the management of 
patient symptoms, which is not acceptable, as far as the holistic patient management 
requirements of the WHO definition of Palliative Care is concerned(6).  In fact, as one paper 
on pain in AIDS patients points out, the success of HAART at improving the life expectancy of 
patients makes it even more important to address symptoms and the burden the symptoms 












Since the use of HAART, studies aimed at assessing symptoms among HIV positive patients 
have found that, although HAART is very effective in controlling disease progression, and 
reversing immunosupression to a certain degree, patients can and do still experience 
symptoms while on HAART(11,14,22,24,25,37,48).  In fact, some studies were able to show 
that HIV positive patients on HAART had significantly more symptoms than those not on 
HAART(24,25).  One study in South Africa found that taking HAART did not reduce the 
symptom intensity experienced by the patient(22).  Two studies have found that patients 
who have changed HAART regimens at some point have a greater risk for having more 
symptoms than patients who had never changed HAART regimens(11,23).   
The Charter Study found that HIV sensory neuropathy was more likely in patients currently 
on HAART, or who had previously been on dideoxynucleoside analogue antiretrovirals such 
as stavudine, didanosine, or zalcitabine (the so-called “D drugs”), while neuropathic pain 
occurred in 38% of those with a sensory neuropathy, with past “D drug” use being a risk 
factors for this pain(48).  This emphasises the point that HAART drugs do have side effects.  
The side-effects are well known and widely published, with sensory neuropathy and 
neuropathic pain being one set of side effects that can occur.  The symptoms that were 
more common among patients on HAART in the study by Peltzer and Phaswana-Mafuya 
were predominantly side effects that could be attributed to HAART(22).  This finding is 
similar to those of Silverberg et al in the USA, among women who changed HAART or 
stopped HAART(11), however both studies also found a broader symptom prevalence than 
only possible HAART side effects, and also found high symptom prevalence in patients who 
were HIV positive but had never been on HAART, thus calling for caution that symptoms 
should not be entirely subscribed to HAART therapy(11,22).  Harding et al also found that, 
although causality could not be established, certain symptoms that were more common in 
men on HAART were also well known side effects of HAART, however the study also found 
that HAART was independently linked to greater symptom prevalence and burden for most 
symptoms on the MSAS-SF(24).  Another study conducted by Harding et al found that being 
on HAART was not associated with any lowering of symptom prevalence or symptom 
distress(23).   These studies support the view that HAART does not at all negate the need for 
symptom assessment and management in the general HIV outpatient clinic.  In fact, from 












patients on HAART is comparable to patients with other advanced disease such as advanced 
malignancy or end stage renal disease(24).   
It is for these reasons that it is important to know what the symptom prevalence and 
burden are among a representative sample of HIV positive patients in South Africa who 
attend outpatient HIV treatment clinics.  We need to know what the symptom prevalence 
and burden are, so as to motivate the health care workers concerned to adequately assess 
patients who attend these treatment clinics, and as a result of assessment, provide the 
appropriate symptom control measures.  This may require the training of health care 
workers and the findings of this study should inform the training needs among HIV clinicians 
and health care workers.   
 
The relationship between symptoms and adherence to HAART 
When considering the impact of HAART on the patient with HIV, it has potential impact on 
the patient’s life expectancy and also their quality of life.  Quality of life is a complex 
measure and includes many factors, but symptom prevalence and burden is an important 
part of the quality of life of a patient with a chronic illness(29).  One of the most notable 
things about HAART is that the medication needs to be taken in its entirety, correctly, 
everyday for the rest of the patient’s life, for it to be of sustained benefit.  This is no small 
ask, and requires a patient who is motivated, well supported and also well educated about 
his/her disease, to be able to manage this requirement.  A study published by Sherr et al 
discussed the difficulties in assessing adherence accurately, and this itself sheds light on the 
demands of HAART adherence on patients who take these drugs.  Sherr at al write that 
adherence requires not only that each dose is taken, but that the timing should be correct 
and that the necessary dietary restrictions for the drugs concerned should be followed 
correctly(31).  It is known that lack of adherence to a HAART regimen by a patient leads to 
failure of viral suppression and immune restoration on those particular drugs used, 
requiring new antiretroviral drugs to be used, and there are a limited numbers (and 
combinations) of these available(31).  In their particular study, patients who were not 
adherent to their HAART regimen had higher psychological symptom burden and higher 












whereas patients who were considered to be fully adherent on HAART were older, had a 
lower psychological symptom burden and global distress scores and reported greater 
satisfaction with their relationship with their doctor and the outcomes from that 
relationship(31).  Lampe et al found an association between symptoms of depression, 
anxiety and other physical symptoms with virological failure on HAART and that this was 
considered for the most part independent of a lack of adherence to HAART(37).  Rodkjaer et 
al found that in their sample of HIV patients in Denmark, 26% had major depression and 
that the risk for poor HAART adherence was almost 6 times higher in depressed patients 
than in those not depressed(38).  Lee et al concluded that “...those on ART, regardless of 
current CD4 cell count or prior AIDS diagnosis, should be targeted for interventions to help 
manage their symptom experience and to assure adequate adherence to their medication 
protocols”(55).  
These studies all highlight the need for clinicians to monitor patients for physical and 
psychological symptoms and to manage these in a manner that is acceptable to the patient 
concerned as well as medically acceptable, so that HAART adherence and virological 
suppression remain optimal and so ensuring the best possible chance for the patient to have 
their disease controlled for as long as possible.  The ultimate goal may be increased survival, 
but that has to be coupled with the goal of attaining and maintaining a desired quality of life 
to ensure the sustainability of the ultimate goal.   
 
The under-treatment of symptoms 
Pain is one of the most investigated individual symptoms in HIV disease.  In 1996, Breitbart 
et al reported that a significant number of patients with AIDS in their sample in New York, 
who experienced pain, had inadequate analgesic treatment for their pain(33).  There has 
been agreement among pain management specialists that adequate pain management for 
patients with HIV disease should employ the same WHO guidelines as for the treatment of 
cancer-related pain, and so, using the Pain Management Index (PMI), 84.1% of patients, in 
the study conducted by Breitbart et al, had pain that was unsatisfactorily treated, and even 
if the investigators used less strict criteria, 49.1% of patients’ pain was still unsatisfactorily 











was insufficient knowledge regarding pain management held by doctors involved in the care 
of HIV patients, and suggested that future research be conducted in this area(33).  In 2001 
in a study in Italy, Del Borgo et al also reported that pain was undertreated(46).  In a 
prospective longitudinal study on pain in Denmark by Frich et al, the PMI score at the 
initiation of the study showed that only 25% of patients were receiving adequate analgesia, 
whereas by the conclusion of the study, 64% of patients had received adequate 
analgesia(13).   
By inference, it can be said that there was found to be under-treatment of depression in
patients in a Danish study on depression in HIV positive patients, as the particular study 
found there to be an under-diagnosis of major depression in this population(38).  
The study done in the USA, by Karus et al, at three different sites also asked the question of
participants whether the patient thought the individual symptoms were being treated or 
not(34).  The results showed that although at least 50% of participants believed that pain,
nausea, difficulty in swallowing and mouth sores were being treated, only a third or less of
patients perceived that they were receiving treatment for a number of other symptoms,
including worrying, feeling sad, feeling nervous, difficulty concentrating, dizziness and sexual
problems(34).  Less than 50% of patients at all sites felt that their neuropathic pain was 
being treated, and there was also under-treatment of gastrointestinal problems such as 
constipation, nausea and vomiting and diarrhoea which, as the authors point out, do have 
available palliative treatments(34). 
As discussed in the introduction, Fontaine et al showed in their multi-centre study 
conducted in France, that physicians displayed a poor to moderate ability in recognising the 
presence of symptoms in their patients(18).  The symptoms most correctly identified were
those that are related to measurable physical signs(18).  This shows that health care
workers are poor at identifying the symptoms experienced by patients. So unless the health
care worker is dedicated to taking a detailed symptom history for each patient on a regular
basis, with provision of adequate time for patients to communicate this effectively and to













To be able to treat pain and the relevant symptoms experienced by patients in a satisfactory 
manner, the necessary medication must also be available.  This may be a challenge in a 
resource-constrained setting.  Harding et al recently published their findings of cross-
sectional research into the availability of and prescribing practices for medication for pain 
and symptom relief in 12 Sub-Saharan African countries, including South Africa(35).  They 
studied the availability of a range of medications available at palliative care sites, and 
although South Africa was among the better performing countries in the region, the findings 
revealed that there are still significant gaps in the provision and supply of opioid analgesia, 
non-opioid analgesia and other medications commonly used for symptom control, despite 
their being “essential drugs”(35).  To be able to adequately treat pain and other symptoms, 
the appropriate medications, as advised by the WHO and other medical evidence, should be 
available for the treating doctor to prescribe, as far as is to be reasonably expected in 
resource constrained settings.  
 
HIV symptom prevalence and burden as compared to that of other chronic 
diseases 
Palliative care started out as being predominantly for people with cancer, and now the 
benefit of palliative care for patients with other chronic diseases, such as advanced cardiac 
and renal disease, is being more widely recognised.  There is evidence to show that patients 
with chronic diseases suffer as much as cancer patients do at the end of life.  Solano et al 
systematically searched the literature for evidence of suffering amongst patients with 
advanced AIDS, Cancer, Heart Disease, Chronic Obstructive Pulmonary Disease and Renal 
disease(56).  What their literature search showed, was that from 64 studies and 18 textbook 
chapters, pain, fatigue and breathlessness had on average, an over 50% prevalence rate for 
all five of these diseases nearing the end of life(27).  Insomnia, anorexia and depression 
were also common symptoms in all these diseases, with not too dissimilar frequencies(27).  
It is thus clear from this informative review of the international literature that the frequency 
of symptoms requiring palliation in cancer patients and indeed other advanced diseases is 











Vogl et al wrote that the symptom prevalence found in their study of AIDS outpatients in 
New York was higher than the average symptom prevalence in a comparative study for 
patients with cancer who were receiving outpatient treatment(10).  Harding et al 
commented that the symptom prevalence and burden of their findings in a UK-based online 
survey, was comparable to patients with advanced malignant disease(24).   
These findings strongly suggest that there is a need for palliation amongst ambulant 
patients with HIV disease, regardless of stage of disease, just as there is a need for palliation 
for patients with cancer and other chronic and advanced diseases. 
The burden of suffering of HIV disease as seen from a Public Health
perspective
In the introductory chapter, I highlighted the significant impact that HIV has had and is 
having on the health status of South Africans. The mortality and the symptom-related
suffering of patients with HIV have also been discussed.  Understanding that palliation is
wider than end of life care and “is applicable early in the course of illness, in conjunction
with other therapies that are intended to prolong life”(6) is important for understanding the 
need for the role of palliative care at all stages of HIV disease. Understanding this,
highlights the very large need for palliation for HIV infected patients in South Africa.  
Disease trajectories have been specifically studied in relation to the end of life functional 
decline that patients exper ence as their disease moves closer to the end of life(57,58).  
However, disease trajectories for chronic disease are helpful in understanding the
unpredictable course of HIV disease, pointing out that even with HAART, HIV is a chronic
disease with an unpredictable course. The difficulty in predicting the course of HIV disease 
should encourage health care workers to involve palliation early in the course of illness, 
rather than delaying palliation and symptom control measures which are able to improve
the quality of life for patients while they still have ample time to enjoy life, and be as active 
and as productive as is possible.
There are studies that show that palliative care does help to minimise the costs of health
care for the provider, however there is a need for more research to assess the patient












should most importantly improve patient outcomes.  Resources for health care are limited 
in most countries in the world, but particularly so in the developing world countries, and so 
the temptation is there to dispense with or ignore palliative care and only focus on curative 
and current types of care(59-61).  Harding writes that “The unhelpful distinction between 
curative and palliative resources is even less useful in poorer countries”(60), motivating that 
both areas actually are required to grow in developing countries, not either curative care or 
palliative care(60).  The research providing evidence for the need for both types of care has 
been conducted predominantly in the developed world, but it does indicate that palliative 
care in HIV management does have desired and important health outcomes for patients(59-
61).  Krakauer highlights this issue also, and makes the crucial point that ensuring the 
adequacy of curative care for poor people in resource constrained settings is the 
fundamental basis from which palliative care should operate(62).  This means that patients 
with cancer should have adequate access to internationally acceptable curative care and for 
patients with HIV, HAART should be the standard basis of medical care(62).  From this basis, 
palliative care should operate together with primary clinical teams, or palliative care may 
have to be provided by the primary clinical team where necessary, to relieve suffering 
amongst those who need it(62). 
 
The issues that these authors highlight are the need for good and appropriate evidence for 
the needs for palliative care amongst patients in the developing world,  the clinical 
effectiveness of palliative care and the cost-effectiveness of quality palliative care in the 
South African setting(59-62).  This study attempts to add to the evidence for the needs for 
palliation that exist amongst patients who attend South African HIV treatment clinics, so 
that more can be done to implement palliative care in this setting and to stimulate further 














Clinical and research tools used to study symptom prevalence and the
burden of symptoms and patient function
There are a number of tools available to be used in the assessment of the patient
experience of illness.  The use of the correct tool is important to obtain the information 
required. The Memorial Symptom Assessment Scale (MSAS) is a validated symptom 
assessment tool developed by Portenoy et al that measures patient rated severity, 
frequency and distress relating to 32 symptoms(63). It has been found clinically that
patients find this tool difficult to use as it requires a fair amount of time and is quite
complex(64). Chang et al have studied the shorter version of the MSAS, namely the
Memorial Symptom Assessment Scale Short Form (MSAS-SF) among cancer patients and
found it to be a valid and quick to use tool for use for symptom assessment(64). The MSAS-
SF measures for the presence of 32 symptoms and their distress or frequency. Distress and
frequency of these symptoms are measured on a 5 point Likert scale.  From the tool can be 
obtained: a physical symptom subscale, a psychological symptom subscale and a global
distress index(64). The global distress index (MSAS-GDI) includes 4 psychological symptoms 
namely – feeling worried, sad, irritable and nervous; and 6 physical symptoms namely – lack
of energy, pain, lack of appetite, feeling drowsy, constipation and dry mouth(64).  The 
physical symptom distress score (MSAS-PHYS) incorporates 12 physical symptoms namely –
lack of energy, pain, loss of appetite, feeling drowsy, constipation, dry mouth, nausea,
vomiting, change in taste, weight loss, feeling bloated and dizziness(64). The psychological 
symptom distress score (MSAS-PSYCH) incorporates 6 psychological symptoms namely –
worrying, feeling sad, feeling nervous, difficulty sleeping, feeling irritable and difficulty 
concentrating(64).  It was found that the MSAS-SF subscale scores were associated
significantly and appropriately with the observer-rated Karnofsky Performance Status which
measures performance and function(64). Importantly, this MSAS-SF has also been used to
study symptoms amongst patients with AIDS: Vogl et al reported that the internal
consistency among HIV patients was a high as in cancer patients(10,64). The MSAS-SF
includes all the commonest symptoms that have been noted in previous studies, and is itself
a commonly used symptom assessment tool for patients with HIV as shown in the literature












The Karnofsky Performance Status Scale (KPS) has been used in the assessment of function
in patients with cancer, HIV and AIDS(10,27,65). Mor et al studied its reliability and validity 
for use in research amongst patients with cancer who had a KPS score of 50% or less and
found good correlation between KPS scores and function and also between KPS scores and
prognosis(65).  Despite the fact that this study was conducted only in patients with cancer 
with a KPS of 50% or less, the authors concluded that this is a reliable and valid tool(65).  
The KPS has been widely used in clinical and research settings for patients with other 
chronic and life-threatening diseases, including HIV and AIDS(10,27). It is a clinician rated
measure of the patient’s functional status. The scale ranges from 0% (dead) to 100%
(normal).  Any score below 70% indicates that the patient is unable to care for him/herself
without assistance(10,27). This tool is suitable for use in this study and was used as an
observer rated tool of performance status.
I did look at other symptom assessment tools and these are evaluated, explaining why they 
were not used in this study. The Missoula-VITAS Quality of Life Index (MVQOLI) is a quality 
of life assessment tool, developed by Byock and Merriman, which assesses a person’s
experience of nearing the end of life(66). It assesses 25 items that measure adaptation to
and integration of a patient’s physical and functional decline, and attainment of life 
completion and life closure.  There are 5 quality of life domains – symptom control, 
function, interpersonal issues, well-being and transcendence. It also measures satisfaction
and importance in each domain(66). The authors Schwartz et al conclude that this tool is 
best used as a clinical tool rather than a psychometric research tool. This tool assesses 
quality of life issues and not direct symptom prevalence. It also is designed for patients
facing the end of their lives which the participants of this study were not necessarily likely to
be facing with imminent certainty, and for all these reasons it was not appropriate for this
survey.
The Wisconsin Brief Pain Questionnaire (WBPQ) was developed by Daut et al in order to 
assess pain intensity and pain interference in mood-related matters and in activity-related 
matters, in patients with pain from cancer or other diseases(67).   Mphahlele et al of the 
School of Physiology of the University of the Witwatersrand have produced validated 
translations of the WBPQ in isiZulu, Setswana and Xitsonga(67).  Mphahlele et al note that 












and so were left out of the translated versions if this was the case(67).  Their manner of 
overcoming the problem of having missing values in the answered questionnaire, was to 
have an interviewer administer the question to the participants, to ensure there were no 
missing values(67).  This is a useful questionnaire to use to assess pain experienced by 
patients with HIV.  It is more informative than the MSAS-SF is on pain – in the description of 
the pain experienced by the patient, and particularly on the number and type of pains, as 
well as the effect of the pain on mood and function(67).  Its particular usefulness in South 
Africa is that it is already translated and validated in the above-mentioned languages(67).   
The aim of this survey is to establish prevalence and burden of pain and other symptoms.  
The MSAS-SF satisfactorily accounts for pain and the burden thereof.  What the MSAS-SF 
does not do is differentiate different areas or types of pain.  This would be useful, but this 
was not the aim of this study and therefore this tool was not utilized in this survey.  It was 
also felt that it would be too burdensome for patients to answer questions from two fairly 
detailed tools.   
Another symptom assessment tool that has been used for HIV in Southern Africa, is The 
Revised Sign and Symptom Checklist for Persons with HIV Disease (SSC-HIVrev)(68).  It has 
72 symptoms, physical and psychological, with eight gynaecological questions, so there are 
64 symptoms which relate to both men and women(68).  This was translated into seven 
languages for the study by Makoae et al, namely Sesotho, Setswana, Siswati, Tswana, 
Venda, Xhosa, and Zulu(20), but these translations were not validated.  The presence of the 
symptoms on the day of the study is enquired about and the intensity of the symptoms (also 
on the day of study) is also enquired about, with the intensity scored as mild moderate or 
severe, therefore on a 3 point Likert scale(68).  Validity and reliability of the original version 
has been studied in a sample in the USA, by Holzemer et al 2001(68).  This symptom 
assessment tool was not used in this study as it is less frequently used in the literature than 
the Memorial Symptom Assessment Short Form (MSAS-SF), thus making it less useful for 
















Rationale for the study 
 
The aim of this research study was to survey the prevalence of symptoms and the burden 
these symptoms pose to the patients attending large HIV treatment clinics in the urban 
greater Johannesburg, Gauteng Province, South Africa.  These patients receive appropriate 
disease-specific care for their HIV disease, however not as much is known about the 
palliative care needs of these patients with this life-threatening illness in this particular 
setting.  Understanding the pain and symptom prevalence and the burden from these 
symptoms among these patients will assist in addressing these needs and in so doing, 
improve the quality of life of patients with HIV who attend outpatient treatment clinics.  
This type of patient-focused management may also possibly improve patient adherence to 
anti-retroviral therapy (HAART), as other studies have suggested.  It is also the hope that 
this study will stimulate further research into the palliative care needs that these patients 





















Aims and Objectives 
AIM 
To survey the prevalence and burden of pain and other symptoms in HIV positive people 
who attend outpatient HIV treatment clinics at Johannesburg’s three adult academic 
hospital complexes, namely the Charlotte Maxeke Johannesburg Academic Hospital, the 
Chris Hani Baragwanath Hospital and the Helen Joseph Hospital. 
OBJECTIVES 
1. To survey the prevalence and burden of pain and other symptoms.
2. To determine the prevalence and burden of symptoms in relation to the WHO stage 
of illness, CD 4 count, viral load, functional status of the patient (as assessed by the 
Karnofsky Performance Status), and in relation to HAART.


















This is a cross-sectional survey with descriptive analysis. 
 
Study Site 
The research was conducted in the outpatient adult HIV treatment clinics at the academic 
hospitals associated with the University of the Witwatersrand, namely the Charlotte Maxeke 




The study population was all of the adult patients who are registered at the above three 




















The following were the inclusion criteria for the selection of participants: 
 Confirmed HIV positive patients attending one of these mentioned outpatient adult 
HIV treatment clinics 
 Patients over the age of 18 years on the day of participation in the study 
 Both male and female patients 
 Patients of any WHO stage of disease 
 Patients who were able to and did consent to take part in the study 
The following were the exclusion criteria for the selection of participants: 
 Patients who were in extreme distress or were very ill on the day, were not invited 
to participate in the study 
 Patients not cognitively able to consent to participation in the study 




The study sample was taken from the patients attending the stated adult HIV treatment 
clinics. 
Simple random sampling was used. To reduce selection bias associated with this method, 
every fifth eligible patient in the queue waiting to see a clinic doctor was invited to 
participate in the study.  The days on which the sampling was done at each clinic was spread 

















Sample size calculations were based on the primary aim of assessing symptom prevalence as 
a proportion.  The assumptions were that if the estimate of prevalence was to be of a 
precision of within 5% of the true value, so that the prevalence can be reported with 95% 
confidence, the largest sample size of 385 participants was obtained for the assumption of 
an initial prevalence of 50%.  Thus, the number of participants required for a confidence 
interval of 95% (5% precision) and for a proportion of 50% prevalence, was calculated to be 
384.16, and this was rounded up to 385 participants.   
This table illustrates the above explanation: 
        |   p         n_p     | 
        |----------------------------| 
  1.  |   .01    15.21274| 
  2.  |   .05     72.9904   | 
  3.  |   .1    138.2976 | 
  4.  |   .2    245.8624| 
  5.  |   .3    322.6944 | 
       |-----------------------------| 
  6.  |   .4    368.7936| 
  7.  |   .5      384.16      | 
  8.  |   .6    368.7936 | 
  9.  |   .7    322.6944 | 
 10. |   .8    245.8624 | 
        |----------------------------| 
 11. |   .9    138.2976 | 
 12. |   .95    72.99042 | 





Sampling was begun on 21 September 2009.  The last participant was recruited on 14 April 















Data Collection Tools 
The Memorial Symptom Assessment Scale Short Form (MSAS-SF) was used to document 
symptoms that the participants had experienced in the last one week, as well as the burden 
for the physical symptoms or the frequency for the psychological symptoms.  This tool is 
validated, as was described in the literature review.  The participants were asked to answer 
yes to any symptom they had had in the past week, and if the symptom was present to 
answer how much it had distressed or bothered them (that is, the burden of the symptom), 
on a five point Lickert scale.  The five point scale ranged from 0, “not at all”, to 4, “very 
much”.  The MSAS-SF was translated into isiZulu and Sesotho, which are the two main 
languages spoken by inhabitants of the Johannesburg region.  The Wits Palliative Care unit 
had previously done these translations of the MSAS-SF.  The method of translation used was 
the method of ‘back translation’.  By this method, one forward translation was conducted 
by first language isiZulu and Sesotho speakers respectively and then a back translation into 
English by separate first language speakers in isiZulu and Sesotho respectively. These 
translations had already been checked, piloted and used successfully.  These translated 
versions were re-checked for meaning, which was found to be satisfactory.  It was decided 
to administer the MSAS-SF as an interviewer-administered tool to assist patients who are 
not adequately literate, and so to keep the method of MSAS-SF administration as uniform as 
possible for all participants. 
The Karnofsky Performance Status tool was used to assess functional status on an 11 point 
scale from 0% to 100%, with 0% being dead and 100% being normal function.  The research 
nurse interviewing the participant assessed their functional status through observation and 
questioning and assigned a value accordingly.   
A Participant Data Sheet was used to record the demographic details of each participant, 
and relevant clinical details obtained from the clinic file of each participant.  The Participant 
Data Sheet was developed by the Principle Investigator (PI), in collaboration with her 











at which the study was conducted, with the aim and objectives of the study in mind. It was 
designed to be simple to use while also collecting the necessary information.  The 
demographic details recorded were: age at last birthday, gender, self-determined ethnicity, 
latest CD4 count with date, latest viral load with date, latest albumin level with date, initial
CD4 count before starting HAART with date, initial viral load before starting HAART with
date, WHO staging, HIV-related diagnoses, diagnoses unrelated to HIV, whether the
participant was on HAART and if so the date of starting, any change in HAART including the 
date/s and previous regimen/s and reason/s for change. This form also included a space to
record the participant’s Karnofsky Performance Status score which was assessed once the
MSAS-SF and clinical information was completed, as above. It included a subjective 
question for the participant to answer once the MSAS-SF had been administered: “Do you
think that any of your symptoms are because of your ARVs? If yes, which symptoms?” 
Data Collection Method 
The number of participants at each site was obtained by dividing the total number required, 
namely 385 participants, by three. Thus, two sites would have 128 participants and one site
would have 129 participants.
Nurses with research experience were required. The department of Wits Palliative Care 
where I worked at the time of the study had two experienced research nurses, Sr Keletso
Mmoledi and Sr Ntombi Hatta. The PI acquainted the research nurses with the research
protocol and trained them in the administration of the MSAS-SF original version and
acquainted them with the translated versions. The Karnofsky Performance Status tool and
the Data Collection sheet were explained and the use thereof assessed.  Sr Mmoledi and Sr 
Hatta had both received formal training in the ethics of research and so were also 
conversant with the ethical norms required. Ethical research methods with regards to this
study were reviewed by the PI with the research nurses. In September 2009, Sr Mmoledi
then started to recruit participants at Helen Joseph Hospital’s HIV clinic, and then also
concurrently recruited participants at Chris Hani Baragwanath Hospital’s HIV clinic.  At each












In January 2010, the team’s other nurse with research experience, Sr Ntombi Hatta, was 
able to take over from Sr Mmoledi with participant recruitment and data collection.  The PI 
acquainted Sr Hatta with the research protocol and she was trained in the use of the MSAS-
SF and the Karnofsky Performance Status tool.  The Data Collection Sheet was also 
explained.  Her understanding and use of these tools was assessed. After being introduced 
to the HIV clinic staff by Sr Mmoledi, she continued the recruitment of participants at Chris 
Hani Baragwanath Hospital and then concurrently also recruited participants and collected 
data at the Charlotte Maxeke Johannesburg Academic Hospital’s HIV clinic, after being 
introduced to that HIV clinic’s staff by the PI.  Sr Hatta then completed the recruitment of 
participants at Helen Joseph Hospital.   
The procedure followed with each participant
Participants were recruited while waiting to see the doctor on the morning of their clinic
visit.  The research nurse would inform the patients in the waiting area about the study and 
what involvement would mean. She would then invite each fifth person in the queue to
consider participation on a purely voluntary basis. It would be explained that this would not
interfere with the person’s visit to the doctor. Those who wished to participate then took
turns to sit with the research nurse, in a private room or area away from other patients to
ensure confidentiality. The research nurse explained the patient information document and
the informed consent document in the language of choice of the participant – either in
English, isiZulu or Sesotho.  The language chosen would be used throughout that
participant’s interview.  If the participant chose to participate, he or she would sign the 
informed consent document. 
The research nurse would then use the participant’s clinic file to extract the data required 
on the Participant Data Sheet.  Once this was done, the research nurse would then use the 
MSAS-SF in the participant’s chosen language.  This involved explaining the purpose of the 
MSAS-SF and what the question was for each symptom.  The MSAS-SF was used as an 
interviewer administered tool, so the research nurse would ask the questions and fill in the 
answers as given by the patient.  The participant was asked if he or she had had the 











the symptom distressed or bothered them, on a scale of 0 to 4.  This was done for each of 
the physical symptoms.  The last four symptoms are psychological and if they were present, 
the participant was asked how often the symptom occurred, also on a scale of 0 to 4.   
Once this was completed, the research nurse would rate the participant on the Karnofsky 
Performance Scale and note this on the Participant Data Sheet.  The research nurse would 
then ask the participant the question on the bottom of the Participant Data Sheet which 
asked if the participant thought that any of these MSAS-SF symptoms were due to their 
ARV’s, and if so, which symptoms.   
Once this was completed, the participant was thanked and that was the end of the 
interview. The participant left with their copy of the patient information sheet.
The Data was and is stored in the Wits Palliative Care Offices in a locked area. The informed
consent documents are stored in a separate file from the data forms and questionnaires, to
ensure anonymity. No identifying details of the participants were written onto the data 
forms and MSAS-SF questionnaires. 
Data analysis
Data was entered by the PI, the research assistant working at Wits Palliative Care, Miss 
Nozipho Zwane, and by the research nurse Sr Hatta. The Participant Data was entered into
Microsoft Access 2007 on a database created by Miss Zwane as guided by the PI. The MSAS-
SF data was entered into Microsoft Excel 2007 onto a spreadsheet created by Miss Zwane,
as guided by the PI. 
During data capturing, the PI did random checks to assess the completeness of the data.  
After completion of the data collection, the PI obtained a random 10% sample of the 
numbers 1 to 385 which was generated using STATA by the Statistician, Edmore Marinda, 
from the University of the Witwatersrand School of Public Health.  These study numbers’ 
data sets were fully double entered by the PI alone, to check the consistency and accuracy 
of the three different data capturers.  There was found to be no marked discrepancy in the 












The Participant Data was transferred to a Microsoft Excel 2007 document.  All the 
Participant Data and the MSAS-SF data were assessed in Microsoft Excel 2007 for outliers by 
the PI.  Frequency pivot tables were created for each variable.  No significant outliers were 
found.  Frequencies are reported as percentages.  Formal statistical analysis was begun 
using STATA by the statistician, from the University of the Witwatersrand School of Public 
Health.  The analysis was however not completed because the statistician experienced time 
constraints and the PI relocated before statistical analysis was adequately completed, 
making it difficult for the statistician and the PI to meet to continue to work on the analyisis.  
Therefore, the analyisis was repeated and completed by Anneli Hardy of the University of 
Cape Town’s Statistical Consulting Service, again using STATA.  The results of the frequencies 
obtained in Excel correlated with those in STATA.  Cronbach’s coefficient alpha was used to 
assess reliability of the MSAS-SF subscales.  One way analysis of variance (ANOVA) was used 
to assess the relationships between the demographic and clinical variables (for example the 
WHO stage) with the MSAS-SF subscale scores.  This was correlated with the Kruskal-Wallis 
equality-of-populations rank test for each correlation of the non-parametric data.  SPSS was 
used to calculate the effect size for the significant comparisons found in these analyses.  In 
STATA, Multiple regression analysis was performed to determine those clinical and 
demographic variables that were predictive of the MSAS-SF subscale distress scores.  STATA 




This study obtained permission from the Research Ethics Committee of the University of 
Cape Town, and from the Committee for Research in Human Subjects (Medical) at the 
University of the Witwatersrand.  See appendix. 
Agreement from the Hospital management and the heads of the HIV clinics concerned was 
obtained once both Research Ethics Committees had granted their approval.   
The research nurse provided an information sheet to each participant, explaining the study 
procedure and aims and the anonymity and confidentiality of each participant.  Consent for 











available for the participants from the research nurses.  The patient hospital number was 
entered only onto the consent form, along with the participant name, only for the purposes 
of allowing extraction of missing laboratory data where this was required if the patient 
record was incomplete on the day of study.  The study number was used for the data set.  
This was been done to ensure patient confidentiality and anonymity which is of paramount 
importance.  The participants were free to exit from study participation at any point.  All 
effort was made to ensure understanding and appreciation of the study, confidentiality and 
the fact of voluntary informed consent.  The participants received on their participant 
information form, the means with which to make contact with the researcher, should the 
participant have had or still has any questions or would like to know the results of the 
survey.   
This survey investigated the symptoms of a medically vulnerable group.  A vulnerable 
person is someone who has limited means of protecting his or her own interests or rights, 
by virtue of lack of power, resources, intellectual or educational abilities. A vulnerable 
group has members with such qualities. Financial, educational, cultural, health care
treatment availability and choice options are issues that play a role in making groups 
vulnerable to research injustices(69).  The medically vulnerable group of HIV positive people 
who do not have many choices or options for obtaining treatment due to their financial
constraints as well as perhaps educational and cultural constraints, is the group this study 
surveyed. There were no overt risks to the participants as the survey involved no study
intervention. The benefits to the group of HIV positive patients in general will be greater
health care worker appreciation of the prevalence and burden of symptoms within this 
population, thus it is hoped this will leading to greater vigilance and improved treatment of
these symptoms in the future.  It was emphasized that neither participation, nor non
participation would lead to a change in the level care for the individual patient. The benefits 
of understanding the symptom prevalence amongst a South African urban HIV positive
population, both on and off Highly Active Antiretroviral Therapy (HAART) who attend an HIV 
treatment clinic, will enable better understanding of the population group we serve and it is
hoped by the researcher that this will lead to better patient care across these clinics as well












No children were included in the study.  All individuals were 18 years or older.  Individuals 
suffering from dementia, mental illness or mental retardation were excluded from the study 
to protect the cognitively vulnerable and to ensure that all symptoms found were the 
experience of the individuals concerned.  The researcher was not and is not a member of 
staff of these clinics and so it was not anticipated that there would be undue pressure due 
to such deference.   This survey was a study of a population that is often financially 
vulnerable, but no compensation was awarded as the study occurred on a day that the 
patient would normally have attended their clinic.   
If and when the research nurses uncovered medical problems during the interviews, they 
referred these patients back to the clinic doctor, or to the palliative care service, or to 
another speciality, as indicated, and with a written referral as needed.  This was not found 
















Participant Data – Demographics 
The Participant Data Sheet is in the Appendix. 
The sample size was 385 participants.  (n = 385) 
Table 1:   Demographic Information 
 
Factor N (%) 
Gender 
   Male 





    Black 





    1 
    2 
    3 







   Yes 




Age mean (std) 
        Median (Q1-Q3) 
        Range 
40.31 (9.1) 
40 (33 - 46)  
24 - 79 






94 (41 - 160)  
2 - 616 






322 (206 - 452)  
4 - 1403 




90 (90 - 90) 





33 (29 - 39) 















The ages of the participants ranged from 22 to 79 years of age.  The mean age was 40.3 
years. See also Table 1. 




Table 2:  Age distribution for statistical analysis 
        Age            |      Frequency     Percent        Cum. 
   1. 18-30  |          52                 13.51          13.51 
   2. 31-44  |        219                 56.88          70.39 
   3. 45+  |        114                 29.61        100.00 

















Of the 385 participants, 292 (75.84%) were female and 93 (24.16%) were male, as depicted 
in the graph.  See also Table 1. 
Graph 2:  Distribution of Gender 
Self-Determined Ethnicity
Three hundred and seventy eight (98.18%) of the 385 participants were black, five (1.30%)
were coloured and two (0.52%) were white, as depicted in the graph below.  See Table 1.












Language used for the interview 
According to each participant’s choice of language used, two hundred (51.95%) of the 
interviews were done in isiZulu; 107 (27.79%) were done in Sesotho, and 78 (22.59%) of the 
interviews were done in English.  This distribution is depicted in the graph below. 

















Participant’s Clinical Data 
  
Initial CD4 Count before starting HAART 
Three hundred and eighty (98.70%) of the 385 participants had an initial CD4 Count.  This 
ranged from <1 – 616 cells/mm³.  The mean CD4 count before starting HAART was 
115.1cells/mm³.  See also Table 1. 
This graph shows the Initial CD4 Counts in groups of: 0-50, 51-100, 101-200, 201-350, 351+:  
This grouping was done after reading the literature(10,17) and using the recent 2010 SA 
DOH HAART guidelines(4).  
















Latest CD4 Count 
All patients had a latest CD4 count.  The latest CD4 Count ranged from 2 to 1403 cells/mm³.  
The mean CD4 Count value was 355.06 cells/mm³.  See Table 1. 
This graph shows the Latest CD4 Counts in groups of:  0-50, 51-100, 101-200, 201-350, 351-
500, 501+.  The addition of the groups 351-500 and 501+ instead of only 350+ was to 
accommodate for the participants with CD4 counts higher than 500, to differentiate the CD4 
count groups further.   




Initial Viral Load before starting HAART 
Two hundred and thirty six (63.90%) of the 385 participants had a viral load recording 
before HAART was started.  The range was from <25 to 21 million copies/ml.  Viral 
suppression was taken to be any viral load not detected by that laboratory doing the test, 
and any viral loads detected from 0 to 40 copies/ml by the laboratory were taken to be 
undetectable, so as to make the data less confounding as some laboratories could detect a 
viral copies of above 25 copies/ml, while others could only detect viral copies over 40 
copies/ml.  Using this cut-off of 40 copies/ml, there were 42 measurements that were 
undetectable before HAART was started.  One hundred and forty nine participants had no 












HAART for those with a viral load measurement that was detectable, was 373 209 
copies/ml.   
This graph shows the breakdown of Initial Detectable Viral Load in groups of <50; 51-200, 
201-1000, 1001-10 000; 10 001-100 000; >100 000 copies/ml. 
Graph 7:  Breakdown of initial detectable viral load values 
 
This graph shows the simpler breakdown of the Initial viral load (VL taken before HAART was 
commenced) for all participants. 












Latest Viral Load 
Not all participants had a latest viral load – only 349 (90.65%) of the 385 participants.  The 
number of patients who had viral suppression is 271, while 78 participants had a detectable 
viral load.  The mean latest viral load was 90 932.59 copies/ml for those 76 patients with a 
detectable viral load.  As for the initial viral load, viral suppression was taken to be any viral 
load not detected by that laboratory, and any viral loads detected from 0 to 40 copies/ml by 
the laboratory were taken to be undetectable.  This graph shows the latest viral load results 
for all the participants as either no value, undetectable, or detectable. 
Graph 9:  Distribution of all latest viral load values 












Latest Albumin Level 
Only 50 of the 385 participants had an albumin level checked according to their clinic file.  
The range was from 14 – 48 g/l.  The mean albumin level was 33.1 g/l.  The National Health 
Laboratory Service (NHLS) reference value for adult normal albumin is 35-52g/l(70).  For 
those participants with an albumin level, 26 had a normal albumin level of equal to or 
greater than 35g/l, and 24 had a low albumin (<35g/l).  No participants had greater than 
normal values.  The graph below represents these findings.  See also Table 1.   
















The WHO stage of disease, as staged at diagnosis was obtained from the participant files for 
each of the 385 participants.  See also Table 1. 
WHO stage 1 - 98 (25.45%) 
WHO stage 2 – 251 (65.19%) 
WHO stage 3 – 30 (7.79%) 
WHO stage 4 – 6 (1.56%) 
For statistical analysis, WHO stages 3 and 4 were combined into one group.  I as follows: 












HIV Related Diagnoses 
HIV related diagnoses were collected from the files for 245 (63.64%) of the 385 participants.  
140 of the participants had no recorded HIV related diagnoses.  There were a total of 406 
HIV related diagnoses.  One diagnosis was considered by the PI as not HIV related.  The 
diagnoses were grouped by the PI as follows:  Possible Cancer (being investigated), 
Premalignant lesion, Cancer, Bacterial Infections, TB, Herpes Zoster, Gastro-Intestinal 
Infection, Warts, MAC, PCP, Constitutional Symptoms, Syphilis, Dementia, Oral Candidiasis, 
Mucocutaneous manifestations (other than Candidiasis), Renal ‘problems’, Non-malignant 
Haematological, Peripheral neuropathy, Lymphadenopathy and other.  The graph below 
shows the frequency of each of these. 
Graph 12:  HIV related diagnoses as grouped by the PI 
 
 
The number of those patients who were recorded as never having a diagnosis of 












Patients taking HAART 
Of the 385 participants, 379 (98.44%) were taking HAART at the time of the interview.  Six 
participants (1.56%) were not on HAART at the time of the interview.  See also Table 1. 
HAART Drugs used 
The drugs that the participants of the study were taking are as follows:  Lamivudine, 
Stavudine, Efavirenz, Nevirapine, Zidovudine, Didanosine, Lopinavir-Ritonavir, Ritonavir, 
Tenofovir, Saquinavir, Atazanavir. 
The graph below depicts the frequency with which each of the drugs was used in the study.











Changes in HAART 
Of the 379 participants who were on HAART, 207 (54.62%) had never changed HAART.  They 
had been stable on HAART since its initiation, 172 (44.68%) had changed HAART regimens at 
least once.  One participant (0.26%) had stopped HAART treatment.  The graph below 
depicts this information. 













Reasons for change in HAART 
The reasons for a change in HAART were grouped into the following categories. 
Table 3:  Reasons for change in HAART 
Reason Frequency  
Lipodystrophy 75 
Neuropathic pain 45 
Raised Lactic Acid or Lactic Acidosis 23 
Virological Failure 16 
Clinical symptoms of failure 12 
Defaulted treatment 8 
Possibility of pregnancy 4 
Hepatitis B infection 4 
Drug Toxicity 3 
Drug resistance 3 
Gyanecomastia 3 
Dyslipidaemia 3 
Non-Specific Clinical Symptoms 3 
Immunological Failure 3 
Anaemia 3 
Liver Abnormalities 3 
Adverse Drug Reaction 2 
Skin Rash 2 
Pancreatitis 1 
Renal Dysfunction 1 
Structured Treatment interruption 1 
Treatment failure 1 
Insomnia 1 
Nausea & Vomiting 1 



















Current Karnofsky Performance Status (KPS) 
Of the 385 participants,  
59 (15.32%) had KPS of 100%, 
269 (69.85%) had KPS of 90%, 
44 (11.43%) had KPS of 80%, 
6 (1.56%) had KPS of 70%, 
1 (0.26%) had KPS of 60%, 
1 (0.26%) had KPS of 50%, 
1 (0.26%) had KPS of 40%, and
4 (1.04%) had no KPS assigned.
The mean KPS score was 80. No participant had a KPS score of less than 40%.
See also Table 1.
To make statistical analysis of the data easier, the KPS scores were grouped as follows:
KPS  40% to 80% 53 (13.91%)
KPS 90% 269 (70.60%) 
KPS 100% 59 (15.49%) 
The subjective question:  “Do you think any of your symptoms are because 
of your ARVs?” 
Of the 385 participants, 236 (61.3%) answered “yes” to this question, and 145 (37.66%) 
answered “no”.  Two participants (0.52%) answered that it was not applicable.  Two more 












The symptoms indicated as being thought to be due to HAART by the 
participants 
The most common MSAS-SF symptoms that participants said were due to their HAART were 
Body Fat Distribution Changes (46.19%) and Numbness/Tingling of hands & feet (37.73%).  
This table indicates the correlation between MSAS-SF symptoms and the symptoms 
attributed to HAART use by the participants. 
Table 4:  Symptoms perceived as due to HAART by the participants 
Symptoms Frequency 
Body fat distribution changes 109 
Numbness/tingling of hands & feet 89 
Other 24 
Changes in skin 15 
All of the symptoms 8 
Weight loss 8 
Itching 8 
Dizziness 6 
Lack of energy 6 
Pain 5 
Swelling of arms & legs 5 
Diarrhoea 4 
Feeling bloated 3 
Shortness of breath 2 
Problems with sexual interest or 
activity 2 
Feeling drowsy 2 
Lack of appetite 2 
Mouth Sores 1 
"I don't look like myself" 1 
Difficulty in swallowing 1 
Change in the way food tastes 1 
Hair loss 0 
Constipation 0 
Feeling Sad 0 
Worrying 0 
Feeling irritable 0 
Feeling nervous 0 
Dry mouth 0 
Nausea 0 
Difficulty concentrating 0 
Sweats 0 
Difficulty sleeping 0 
Cough 0 












Memorial Symptom Assessment Scale –Short Form (MSAS-SF) 
A copy of the MSAS-SF is found in the Appendix. 
Symptom prevalence and burden 
The prevalence of all the symptoms is shown in Table 2. 
Table 5:  Prevalence of all symptoms by MSAS-SF 
Symptom Prevalence  n (%) 
Feeling sad 249 (64.68%) 
Feeling irritable 239 (62.08%) 
Numbness/tingling in hands & feet 235 (61.04%) 
Worrying 235 (61.04%) 
Problems with sexual interest or 
activity 
200 (51.95%) 
Pain 197 (51.17%) 
“I don’t look like myself” 188 (48.83%) 
Feeling nervous 156 (40.52%) 
Lack of Energy 155 (40.26%) 
Sweats 150 (38.96%) 
Weight loss 150 (38.96%) 
Feeling bloated 147 (38.98%) 
Feeling drowsy 139 (36.10%) 
Changes in skin 136 (35.32%)
Difficulty concentrating 131 (34.03%)
Constipation 121 (31.43%)
Itching 116 (30.13%) 
Lack of appetite 100 (25.97%) 
Cough 98 (25.45%)
Dizziness 94 (24.42%) 
Swelling of arms or legs 92 (23.90%) 
Difficulty sleeping 89 (23.12%) 
Dry mouth 89 (23.12%) 
Shortness of breath 71 (18.44%) 
Nausea 67 (17.40%) 
Diarrhoea 59 (15.32%) 
Problems with urination 55 (14.29%) 
Mouth sores 55 (14.29%) 
Change in the way food tastes 52 (13.51%) 
Hair loss 35 (9.09%) 
Vomiting 23 (5.97%) 












All participants had at least one symptom.  The mean number of symptoms (±SD, range), of 
the 32 symptoms on the MSAS-SF, that participants experienced was 10.24 (± 5.71, 1-28).   
All four psychological symptoms (feeling sad, feeling irritable, worrying and feeling nervous) 
were in the top ten most prevalent symptoms, with feeling sad being the most prevalent 
symptom overall.  The top ten symptoms are, in order from most prevalent:  feeling sad, 
feeling irritable, numbness/tingling in hands and feet, worrying, problems with sexual 
interest or activity, pain, “I don’t look like myself”, feeling nervous, lack of energy and 
sweats. 
Six symptoms had more than 50% prevalence, with four having more than 60% prevalence.  
They are:  feeling sad (65%), feeling irritable (62%), numbness/tingling in hands & feet 
(61%), worrying (61%), problems with sexual interest or activity (52%) and pain (51%).   
High frequency for the psychological symptoms is taken as those occurring frequently or 
almost constantly.  High distress for physicals symptoms is taken as any symptom distress 
described as quite a bit or very much.  This has been done in other studies, by Vogl et al and 
Wakeham et al(10,17).   
Table 6 shows the distress ratings for the physical symptoms. 
Table 6:  Burden/Distress for Physical symptom:  including High Distress (%) for Physical 
Symptoms* 







































































































*High distress for physical symptoms = Quite a bit and Very much























































































































































































































































































Table 7 shows the frequency ratings for the psychological symptoms. 
Table 7:   Frequency of Psychological Symptoms:  including High Frequency (%) for 






















































*High Frequency of psychological symptoms = Frequently and Almost constantly 
 
The high frequency of the psychological symptoms was over 48% for each of the four 
psychological symptoms, with the symptom with the highest frequency being feeling 
irritable, at 60%. 
The highest “high distress” generated by the physical symptoms was for “I don’t look like 
myself”, at 71%.  ‘Problems with sexual interest or activity’ was the second most highly 
distressing symptom if it occurred, at 68% high distress.  The high distress for numbness or 
















Subscales are generated from the MSAS-SF, as described in the literature review.  The 
subscales are the Global Distress Index (MSAS-GDI), the Physical Symptom Subscale score 
(MSAS-PHYS), the Psychological Symptom Subscale score (MSAS-PSYCH) and the Total 
Memorial Symptom Assessment Score (TMSAS).  The subscale scores for this study are read 
as the mean MSAS-GDI, mean MSAS-PHYS, mean MSAS-PSYCH and the mean TMSAS.  A 
constitutional symptom constellation was formed, using five constitutional symptoms, 
namely lack of energy, sweats, weight loss, lack of appetite, and feeling drowsy. 
The Cronbach’s coefficient alpha for MSAS-GDI was 0.7939; for MSAS-PHYS was 0.7657; for
MSAS-PSYCH was 0.7873.  The Cronbach’s alpha coefficient for TMSAS was 0.8784. The 
Cronbach’s alpha coefficient for the constitutional symptom subscale was 0.5931.
The mean (±SD, range) MSAS-GDI score was 1.19 ± 0.89 (0-3.84). 
The mean (±SD, range) MSAS-PHYS score was 0.80 ± 0.71 (0-3.66).  
The mean (±SD, range) MSAS-PSYCH score was 1.27 ± 1.06 (0-4). 
The mean (±SD, range) TMSAS score was 0.90 ± 0.63 (0.25-3.125).
The mean (±SD, range) Constitutional symptom score was 1.04 ± 0.94 (0-4). The use of this 
subscale is new and was not validated.
The mean number of psychological symptoms experienced, out of a possible six symptoms 
(worrying, feeling sad, feeling nervous, difficulty sleeping, feeling irritable, and difficulty 
concentrating) was 2.85 symptoms.  The mean number of physical symptoms experienced, 
out of a possible 12 (lack of appetite, lack of energy, pain, feeling drowsy, constipation, dry 
mouth, nausea, vomiting, change in taste, weight loss, feeling bloated, and dizziness) was 
3.46.
See Figure 1 below for the Boxplot distributions of the scores for MSAS-GDI, MSAS-PHYS, 












Figure 1:  This Boxplot shows the distributions of the scores on the subscales MSAS-GDI, 
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Normality/Distribution of the data 
The Shapiro-Francia W’ test for normal data was applied to test the normality of the data. 
The results show that the sum of the psychological symptoms (psychsum) has a near normal
distribution, but the physical symptom sum (physsum) is not normally distributed with few 
patients experiencing a very large number of symptoms, and the sum of all the symptoms 
(symptomsum) has a near normal distribution, but with relatively few patients experiencing
a very large number of symptoms. The MSAS-PSYCH score and the MSAS-PHYS score are
not normally distributed, with a logarithmic type curve, showing that relatively few patients 
had very high psychological and physical distress respectively. The MSAS-GDI score is also 
not normally distributed, but with a flatter curve, but also showing that relatively few 
patients had very high global distress.  See Figure 2 below.












Correlation of MSAS-SF with demographic and clinical factors 
 
The p value was set at 5% (p<0.05) for significance. 
The Spearman correlation found that there was a large and significant correlation between 
MSAS-PSYCH and MSAS-PHYS; there was a very large and significant correlation between 
MSAS-GDI and MSAS-PHYS and also between MSAS-GDI and MSAS-PSYCH.  See Figure 3.  
There was a very small but significant correlation between age and MSAS-PHYS.  There was 
no correlation between the initial CD4 count and any of the MSAS-SF subscales, nor 
between the latest CD4 count and any of the MSAS-SF subscales.  See Figure 4.  There was 
also no correlation between the latest viral load and any of the MSAS-SF subscales.  Further 
statistical correlations were performed and will now be discussed individually. 













Figure 4:  The Scatter plots show the relationships between the three MSAS-SF subscales 
and age, initial CD4 count and latest CD4 count: 
Initial CD 4 count versus MSAS-SF Subscales
The comparisons between the initial CD4 counts and the MSAS-SF subscales showed no
significant differences between the CD4 count groups (<50, 51-100, 101-200, >200) with any
of the subscales, namely MSAS-GDI, -PHYS, -PSYCH.  The p values were all > 0.05 for the
Kruskal-Wallis equality-of-populations rank test.  
Latest CD 4 count versus MSAS-SF Subscales 
The Kruskal-Wallis equality-of-populations rank test for the nonparametric data, suggests no 
difference in distribution across the categories of the latest CD4 groups (<50, 51-100, 101-
200, 201-350, 351-500, 500+) in any of the three MSAS-SF subscales, MSAS-GDI, -PHYS, or -











Latest Viral Load versus MSAS-SF Subscales 
The Pearson correlation showed no correlation between latest viral load and MSAS-PSYCH, a 
small correlation between latest viral load and MSAS-PHYS, and an even smaller correlation 
between latest viral load and MSAS-GDI.   However, no significance was found for the 
correlations between the latest viral load and the MSAS-PHYS and the MSAS-GDI. 
Latest Viral Load versus Constitutional Symptoms 
The latest viral load, either detectable or not, was compared to the grouping of 
constitutional symptoms, namely lack of energy, sweats, weight loss, lack of appetite, and 
feeling drowsy, and no significant difference in these symptoms was found between those 
with a detectable viral load and those whose viral lad was undetectable.  This was according 
to the Two-sample t test with equal variances, and confirmed with the Two-sample 
Wilcoxon rank-sum (Mann-Whitney) test. 
Latest Viral Load versus Perception that symptoms were due to HAART
The latest viral load, either detectable or not, was compared to the perception that
symptoms were due to HAART, either yes, or no. This was tested using a chi-square test of
independence. The results show that 180 participants with an undetectable viral load
(66.18% of participants with an undetectable viral load) responded ‘Yes’ to the question of
whether they thought their symptoms were because of their HAART, compared to 40 
participants with a detectable viral load (52.63% of participants who had a detectable viral 
load). The chi-square=4.6868, and p=0.030. The effect size for the relationship between the 
latest viral load and the perception that symptoms were due to HAART, was measured, with
a Phi value of -0.116.
Latest Albumin level versus MSAS-SF subscales 
To asses the relationship of the albumin level to the MSAS-SF subscales, two groups of 
albumin level were compared:  a) low albumin - less than 35g/l or b) normal albumin - 
greater than or equal to 35g/l.   There was no significant difference between albumin groups 
according to the sum of all symptoms, as calculated by the Two-sample t test with equal 
variances.  The low albumin group seemed to show a greater mean symptom prevalence 
(9.333333 vs 8.961538) but this was not significant.  The Two-sample Wilcoxon rank-sum 
(Mann-Whitney) test showed that there was no significant difference between the albumin 











When comparing the albumin groups with the MSAS-GDI, MSAS-PHYS and MSAS-PSYCH, the 
Two-sample t test with equal variances and the Two-sample Wilcoxon rank-sum (Mann-
Whitney) tests were used, and there was no statistically significant difference for the MSAS-
SF subscales by the albumin groups.  The group with a normal albumin level had a greater 
mean MSAS-PSYCH score (1.25641) than those with a low albumin level (0.7777778), but 
the difference was not significant. 
WHO stage versus MSAS-SF Subscales
The WHO stages as grouped for statistical purposes were compared to the MSAS-PSYCH, 
MSAS-PHYS and MSAS-GDI using one way ANOVA but because the data was not normally 
distributed and there was unequal variance, the Kruskal-Wallis equality-of-populations rank
test was used to confirm the findings and is the statistic used to report the findings. There
are significant differences for MSAS-PSYCH and MSAS-GDI and there are also differences for
MSAS-PHYS.
For MSAS-GDI, one way ANOVA does show a significant difference, which is confirmed by 
the Kruskal-Wallis equality-of-populations rank test, where the chi-squared is 32.148 with 2 
d.f. with a probability of 0.0001. For MSAS-GDI, WHO stage 1 and 2 and are significantly
different (p=0.0001), as are stages 3&4 compared to stage 1 (p=0.0001), but stage 2 is not
significantly different to stages 3&4 (p=0.363).
The Kruskal-Wallis equality-of-populations rank test with chi-squared = 8.135 with 2 d.f. and
probability = 0.0171, suggests that the distribution of MSAS-PHYS is not the same across the 
WHO stage groups, but with no statistical significance, with p>0.1 for each of the
comparisons on the Scheffe test.
For MSAS-PSYCH, WHO stage 1 compared to WHO stage 2, there was a significant difference 
with WHO stage 2 participants experiencing more frequent psychological symptoms than 
participants who were staged WHO 1 (p=0.0001).  For MSAS-PSYCH, this was also true for 
WHO stages 3 & 4 compared to stage 1 (p=0.0001), but the relationship was not significant 












populations rank test confirmed that this was correct for the non-parametric data used, chi-
squared =  37.891 with 2 d.f with the probability = 0.0001. 
See Figures 5, 6 and 7:  The Boxplots for each of these three relationships are found on the 
subsequent pages.  
‘1’ denotes WHO group 1 
‘2’ denotes WHO group 2 
‘3’ denotes WHO groups 3 and 4 













Figure 6:  This is the boxplot distribution of MSAS-PHYS scores according to WHO groups: 
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The effect sizes for the relationships between WHO groups and the MSAS-SF subscales were 
tested using SPSS.  The effect size for the relationship between the WHO stage and MSAS-
GDI was measured by an eta value of 0.258.  The effect size for the relationship between 
WHO stage and MSAS-PHYS was measured by an eta value of 0.102.  The effect size for the 















Karnofsky Performance Status (KPS) versus MSAS-SF Subscales 
 
The KPS groups for statistical analysis and comparisons are:  KPS 40-80%; KPS 90% and KPS 
100%.  The Kruskal-Wallis equality-of-populations rank test was applied due to the unequal 
variance. 
For MSAS-GDI, the differences by KPS groups were significant, especially for the comparison 
between the groups with KPS 100% and those with KPS < 100%.  Kruskal-Wallis equality-of-
populations rank test reported a chi-squared value of 26.602 with 2 d.f. and a probability of 
0.0001.  The difference between the groups KPS 40-80% and KPS 90% was only just 
significant (p=0.042).  The difference between the groups KPS 40-80% and KPS 100% was 
significant with p<0.001, as for the difference between the groups KPS 90% and KPS 100%. 
For MSAS-PHYS, the differences by KPS groups were significant for all the group 
comparisons, and especially for the comparison between the groups with KPS 100% and 
those with KPS <100%.  Kruskal-Wallis equality-of-populations rank test reported a chi-
squared value of 27.343 with 2 d.f. with probability of 0.001.  The difference between 
groups KPS 40-80% and KPS 90% was significant with p=0.19. The difference between 
groups KPS 40-90% and KPS 100% was also significant with p<0.001.  The difference 
between groups KPS 90% and KPS 100% was significant with p=0.001. 
A comparison of the KPS scores to the MSAS-PSYCH subscale seemed to suggest that the 
relationship between those with KPS 40-80% compared to those with KPS 100% (p<0.001), 
and KPS 90% compared to KPS 100% (p=0.001) were significant, but they need to be 
reported with caution. There was no significant relationship between the group with KPS 40-
80% and the group with KPS 90% (p=0.220).  The Kruskal-Wallis equality of populations rank 
test reported a chi-squared of 21.816 with 2 d.f. and probability of 0.0001, showing that the 
distribution of MSAS-PSYCH was not the same across the groupings of KPS. 
 












Figure 8:  This is the boxplot distribution of the MSAS-GDI scores according to KPS groups: 
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Figure 9:  This is the boxplot distribution of MSAS-PHYS scores according to KPS groups: 
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The effect sizes for the relationships between the KPS groups and the MSAS-SF subscales 
were tested in SPSS.  The effect size for the relationship between the KPS groups according 
to MSAS-GDI was measured by an eta value of 0.259.  The effect size for the relationship 
between the KPS groups according to MSAS-PHYS was measured by an eta value of 0.255.  
The effect size for the relationship between the KPS groups according to MSAS-PSYCH was 














Age versus MSAS-SF Subscales 
Although the Spearman correlation found a very small but significant correlation between 
MSAS-PHYS and age, when comparing the age categories with MSAS-PSYCH, -PHYS, -GDI 
subscales, according to the Kruskal-Wallis equality-of-populations rank test for each 
subscale, there was no significant difference for any of the subscales by age group  
 
Gender versus MSAS-SF Subscales 
The comparison of gender groups versus the MSAS-SF subscales did reveal differences. 
For MSAS-GDI, according to the two-tailed result on the Two-sample t test with equal 
variances, the p value is 0.0207, which shows significance.  The mean MSAS-GDI for females 
is 1.259231, while the mean MSAS-GDI for males is 1.013763.  
For MSAS-PHYS, according to the two-tailed result on the Two-sample t test with equal 
variances, the p value is 0.0424, which is just significant.  The mean MSAS-PHYS for females 
is 0.8484433, while the mean MSAS-PHYS for males is 0.6767025. 
For MSAS-PSYCH, according to the two-tailed result on the Two-sample t test with equal 
variances, the p value is 0.0400, which is just significant.  The mean MSAS-PSYCH for females 
is 1.336187, while the mean MSAS-PSYCH for males is 1.077061. 
The effect sizes for the relationships between gender and the MSAS-SF subscales were 
tested using SPSS.  The effect size for the relationship between gender and MSAS-GDI had 
an eta value of 0.118.  The effect size for the relationship between gender and MSAS-PHYS 
had an eta value of 0.104.  The effect size for the relationship between gender and MSAS-















Pain versus MSAS-PSYCH 
The presence of pain (as reported yes or no on the MSAS-SF questionnaire) was compared 
to the psychological distress rated by the MSAS-PSYCH. The findings show that patients who 
report the presence of pain, regardless of distress rating, had greater MSAS-PSYCH scores.  
The variances were not equal between the two groups, and so the Two Sample T test for 
unequal variances was used and suggested that the difference in mean scores on the MSAS-
PSYCH is statistically significant on the one tailed test with t = -5.4228 and Pr(T < t) = 0.0000.  
The group with no pain had a lower mean MSAS-PSYCH score (0.9849291) than that for the 
group with pain (1.549069).  This was confirmed by the Two-sample Wilcoxon rank-sum 
(Mann-Whitney) test with a probability of 0.0000.  The effect size for the relationship 
between pain and the MSAS-PSYCH subscale was tested in SPSS, finding an eta of 0.266.  
 
Previous Change in HAART versus Symptom Prevalence and MSAS-PHYS 
When comparing any previous change in HAART regimen (either a change or no change) to 
symptom prevalence, there was no significant difference found in symptom prevalence 
between the two groups.  The group who had had HAART changed did have a slightly higher 
mean number of symptoms (10.60694) than the group who had not had a change in HAART 
(9.757282) but this was not significant.  When comparing any previous change in HAART 
regimen to MSAS-PHYS, the group that had changed HAART had a slightly higher MSAS-PHYS 
distress score (0.8535646), than those who had not changed HAART (0.7450427), but this 
was not a significant difference. 
 
Months on HAART versus Symptom Prevalence 
The number of months on HAART was compared to the sum of all the symptoms (symptom 
sum).  The correlation coefficient between the two variables is -0.0061 which suggests that 














Past or Present Tuberculosis versus Symptom Prevalence 
A past history of tuberculosis (TB) or present TB was related to symptom prevalence, 
showing that compared to those who had never had TB, those who had had a diagnosis of 
TB had a greater mean number of symptoms (11.225 symptoms) than those who had never 
had TB (9.922 symptoms).  Two-sample t test with equal variances suggested significance 
with a probability of 0.0295, but this was not confirmed by the Two-sample Wilcoxon rank-
sum (Mann-Whitney) test, although it approached significance with a probability of 0.0561.   
The effect size for the relationship between past or present TB and symptom prevalence 





Multiple regression analyses were performed in STATA, with each of the four MSAS-SF 
subscales as the dependent (or response) variables.  The list of predictors (independent 
variables) in the models were as follows:   
WHO stage, with WHO stage1 as the reference category 
KPS, with KPS group3 (=KPS 100%) as the reference category 
Gender, with female gender as the reference category 
Past or present Tuberculosis, with this diagnosis absent as the reference category 
Change in HAART, with no change as the reference category 
Latest CD4 count 
Initial CD4 count 












The models excluded 6 patients as there were 6 patients who were not taking HAART at the 
time of the study, but this was not deemed a large number and so would not affect the 
result or applicability of the model. 
 
For MSAS-GDI, the F value is 5.02 with a probability of 0.0000.  The R-squared value is 
0.1318 with an Adjusted R-squared value of 0.1055, indicating that this model explains 
10.55% of MSAS-GDI.  The significant contributors were KPS 40-80%, KPS 90%, WHO stages 
2, 3 and 4, and female gender.  KPS 40-80% had the largest Beta value, indicating that this 
group gave the largest contribution to the model. 
Table 8:  Regression analysis statistics for MSAS-GDI  
     MSAS-GDI  |      Coef. Std. Err.      t          P>|t|            Beta 
-------------+-------------------------------------------------------------------------------- 
  Gender_2  |  -.3107558     .1147813     -2.71      0.007        -.147456 
          TB  |  -.0496682     .1137387     -0.44      0.663        -.0234668 
    WHO2_2  |   .4188622     .1137882     3.68        0.000         .2178426 
    WHO2_3  |   .4843509     .2014533     2.40        0.017         .1482123 
    KPS2_1  |   .8326838     .191629       4.35        0.000         .3081274 
    KPS2_2  |   .4131511     .1356941     3.04        0.003         .2044811 
Changed HAART|   .1292097     .0959767     1.35        0.179         .0720752 
   Latest CD4  |  -.0001834     .0002312     -0.79       0.428        -.0447956 
  Initial CD4  |  -.0000984     .0004511     -0.22       0.827         -.0113267 
Latest viral Load|  -.1417831     .116466       -1.22       0.224         -.0654773 
 Constitutional  |   .6274269     .1888556     3.32         0.001        





















For MSAS-PHYS, the F value is 3.58, with a probability of 0.0002.  The R-squared value is 
0.0976, with an Adjusted R-squared value of 0.0704 indicating that this model explains 
7.04% of MSAS-PHYS.  The significant contributors were KPS score 40-80% , KPS 90%, female 
gender and latest CD4 count, with KPS 40-80% obtaining the largest Beta value and so 
showing that this group gave the largest contribution to the model. 
Table 9:  Regression analysis statistics for MSAS-PHYS 
    MSAS-PHYS  |      Coef.  Std. Err.     t  P>|t|   Beta 
-------------+------------------------------------------------------------------------------------- 
  Gender_2 |  -.2564952   .0927321  -2.77     0.006  -.1535795 
     TB  |  -.0372929   .0918897  -0.41     0.685  -.0222338 
    WHO2_2 |   .0736877   .0919297  0.80   0.423  .048359 
    WHO2_3 |  -.0514441   .1627546  -0.32     0.752  -.0198642 
    KPS2_1   |   .7078632   .1548175  4.57   0.000   .3305296 
    KPS2_2  |   .3259508   .1096276  2.97   0.003 .2035669
Changed HAART|   .1329433    .0775398    1.71    0.087  .0935768
Latest CD4 |  -.0003871   .0001868  -2.07     0.039 -.1193471
Initial CD4 |   .0001268   .0003645  0.35   0.728 .0184133
Latest viral Load|  -.0620163    .0940932    -0.66    0.510   -.0361396 
 Constitutional   |   .5866991   .1525768   3.85   0.000 
For MSAS-PSYCH, the F value is 4.69, with a probability of 0.0000. The R-squared value is
0.1242, with an Adjusted R-squared value of 0.0977 indicating that this model explains
9.77% of MSAS-PSYCH.  The significant contributors were KPS 40-80%, KPS 90%, WHO stage 
2, 3 and 4, and female gender. Again KPS 40-80% had the largest Beta value, indicating this 
group was the largest contributor to the model. 
Table 10: Regression analysis statistics for MSAS-PSYCH 
   MSAS-PSYCH  |      Coef.    Std. Err.         t         P>|t|                     Beta 
-------------+------------------------------------------------------------------------------------- 
 Gender_2 |  -.2748675    .1375191  -2.00     0.046  -.1093356 
      TB  |  -.1005091    .1362699  -0.74     0.461  -.0398085 
    WHO2_2 |   .5208049    .1363292  3.82     0.000   .2270606 
    WHO2_3 |   .6887124    .2413605  2.85     0.005   .1766677 
    KPS2_1  |   .9075492    .2295901  3.95     0.000  .281524 
    KPS2_2  |   .4713213    .1625746  2.90     0.004   .1955494 
 Changed HAART|   .1577696  .1149894   1.37     0.171   .073775 
 Latest CD4 |   .0000258    .0002771  0.09     0.926   .0052833 
 Initial CD4 |  -.0001058    .0005405  -0.20     0.845  -.0102076 
Latest viral load |  -.1870735    .1395375  -1.34     0.181   -.0724226 












For TMSAS, the F value is 5.65, with a probability of 0.0000.  The R-squared value is 0.1459, 
with an Adjusted R-squared value of 0.1201, indicating that this model explains 12.01% of 
TMSAS.  The significant contributors were KPS 40-80%, KPS 90%, WHO stages 2, 3&4, female 
gender and a change in HAART.  The contributor with the largest Beta value was KPS 40-
80%, indicating that this group conferred the largest contribution to the model. 
Table 11:  Regression anaylsis statistics for TMSAS 
       TMSAS  |      Coef.    Std. Err.      t      P>|t|                     Beta 
-------------+------------------------------------------------------------------------------------- 
  Gender_2  |  -.1846685     .0797602    -2.32     0.021                -.1250726 
          TB  |  -.0082346     .0790356    -0.10     0.917                -.0055532 
    WHO2_2  |   .2444412      .07907          3.09    0.002                 .1814563 
    WHO2_3  |   .2967827      .1399875     2.12     0.035                  .129625 
    KPS2_1  |    .693013       .1331607     5.20     0.000                 .3660308 
    KPS2_2  |   .3428021      .0942922     3.64     0.000                 .2421664 
 Changed HAART|   .1422743     .0666931     2.13     0.034                 .1132774 
 Latest CD4  |  -.0001713      .0001607    -1.07    0.287                 -.059753 
 Initial CD4  |   .0000307      .0003135     0.10     0.922                 .0050484 
Latest viral load |  -.0796979     .0809308    -0.98     0.325                -.0525339 




The diagnostics were checked and no serious violation of the assumptions was found.  The 
heteroskedacity  and multicollinearity were acceptable, as was the scatter plot of residuals.  




















This cross-sectional survey was conducted in order to evaluate the prevalence and burden
of pain and other symptoms amongst the HIV clinic attendees of the three HIV treatment
clinics in Johannesburg, Gauteng, which formed the population group of the study. The 
prevalence and symptom burden was then related to the various demographic and clinical 
factors to be able to determine relevant and significant relationships which could inform 
clinical work in the field of HIV Medicine and Palliative Medicine in South Africa.  
International research has shown that palliative care should be integrated into routine HIV 
care, as symptoms have been found to be under-reported and under-treated in outpatient
HIV treatment clinics(10,24,49,50,60,62).
Demographics
The demographics of age, gender and ethnicity among the participants of this study are 
consistent with the 2008 National HIV Prevalence, Incidence, Behaviour and Communication
Survey(3), and with the 2009 National Antenatal Sentinel HIV and Syphilis Prevalence
Survey(2).  Three other Southern African HIV symptom prevalence studies have found
similar percentages of females and males(19,20,22). The difference in symptom prevalence
and burden between males and females has been found previously in the literature. Vogl et
al found that for certain symptoms (eight in total), men reported higher distress while for
other symptoms (two), women reported higher distress, but overall they found that men 
and women had a similar symptom prevalence(10). A study in San Francisco found that
women were significantly more likely than men to have more symptoms and greater 
symptom burden(25).  In South Africa, in a hospice population, it was found that women 
reported more anxiety than men(19).  A study on pain in AIDS patients in New York found
that women more often had headaches and radiculopathy than men(12). However, 
Southern African studies have found no significant differences between men and women for
symptom prevalence(20) or intensity(22). Health seeking behaviour in men and women











different between the genders and this may very well be skewing the data findings.  It is not 
possible to ascribe a causal relationship to the differences found in this study and in other 
studies, but the differences may be clinically important.  This may be particularly so, in 
relation to the poor family, social and economic contexts in which many HIV infected 
women in South Africa find themselves.  These findings may however, not be of clinical 
assistance, as both men and women do have symptoms and do experience suffering as a 
result of their symptoms.  Health care workers should not exclude men from screening for 
symptoms as a result of the findings of this study.  This area requires further research to 
clarify the findings of various studies that show differences in symptom prevalence and 
burden between males and females, and also to search for the reasons for these 
differences, if they are confirmed to be significant differences. 
This study found no significant difference for any of the MSAS-SF subscales of symptom
distress by age group.  The age grouping for statistical purposes may have had a role to play 
in the fact that no differences were found. The important finding here is that adult patients
of all ages appear to experience symptoms and burden from symptoms.  
The number of participants choosing to conduct their interview in English may represent
literacy and educational level, with a comfortable level of English comprehension. The 
choice of conducting the interview in English was entirely the patient’s own decision as the 
questionnaire was available in isiZulu and Sesotho.  The choice to conduct the interview in
English may have been because the participants had a first language other than isiZulu and
Sesotho and were more comfortable in English than either of these two languages. Another 
reason may be that health care workers in South Africa predominantly do communicate in
English and so the participants may have felt more used to this language for discussing 
medical matters. Whatever the primary language used the research nurses were able to
speak with the participants in English, isiZulu and Sesotho, so the meaning of questions 












Symptom Prevalence and Symptom Burden  
The high prevalence of symptoms and the high symptom burden experienced by the 
participants of this study indicate a high degree of unmet symptom control and underline 
the palliative care needs amongst the patients of the three HIV treatment clinics which were 
surveyed.  These findings suggests that either patients under-report their symptoms to their 
doctors, or that their doctors do not ask their patients about symptoms and therefore are 
unaware of the symptoms needs, or that the doctors are unaware of treatment and 
management options for these symptoms and palliative care needs.  All of these possibilities 
may be present and are reported in international literature as barriers to meeting patients’ 
needs with regard to symptom control(10,18,23,24).  These findings raise the questions of 
whether patients are empowered to report symptoms, or whether doctors are ignoring 
symptoms and the distress associated with these symptoms?  The mean number of 
symptoms experienced by this cohort of patients is similar to the mean number of MSAS-SF 
symptoms experienced by the men in the UK-based online survey, of whom over half were 
on HAART(24), while it is lower than the mean symptom number of other international 
studies which have used the same symptom assessment tool(10,17,23).  A study of the 
symptoms experienced by advanced AIDS patients in Soweto, South Africa, found a lower 
mean number of symptoms(19), however the assessment tool  in the Soweto study had 
fewer symptoms than the MSAS-SF, indicating that unless the clinician specifically asks 
about specific symptoms, the presence of symptoms may be under-estimated and under-
assessed and the patient will be under-treated.  Clinicians need to actively seek symptoms 
rather than rely on symptoms being reported by patients.  The findings points to a high 
symptom prevalence amongst this study population, regardless of disease stage or the use 
HAART.   A study assessing symptom prevalence and burden amongst cancer patients who 
were already receiving palliative care in South Africa and Uganda, found more symptoms 
among the advanced cancer patients than among the participants of the current study(71).  
There are however, common symptoms described in both studies, showing that the 
symptoms of patients with HIV who receive outpatient HIV care are comparable to the 
symptoms of patients with incurable cancer who are receiving palliative care.  The question 
must be asked – why do the patients with advanced cancer receive palliation for their 
symptoms, while patients with HIV do not receive palliation for the same symptoms?  Is this 












recognised the applicability of palliative care to other disease entities?  Clinicians may also 
be unaware of the applicability of palliative care “early in the course of” chronic disease(6), 
including for patients with HIV who attend outpatient HIV treatment clinics. 
Six symptoms had more than 50% prevalence in this study.  They are:  feeling sad, feeling 
irritable, numbness/tingling in hands & feet, worrying, problems with sexual interest or 
activity and pain.  The next most common symptoms are “I don’t look like myself”, feeling 
nervous and lack of energy.  In their online survey in the UK, Harding et al found a very 
similar profile of top symptoms, with the only marked difference between these samples, 
being that their participants had a greater frequency of difficulty sleeping, difficulty 
concentrating and feeling drowsy(24).  The outpatient population study conducted in 
London had a very similar symptom prevalence profile to the online survey although 
sadness, worry and irritability seemed to be more prevalent amongst the participants of the 
online survey(23,24).  It is significant that there is a distribution of symptoms across 
emotional, psychological and physical domains.  This highlights the importance of the 
comprehensive response of palliative care described in the WHO definition of palliative care 
as “assessment and treatment of pain and other distressing problems, physical, psychosocial 
and spiritual”(6).  The participants of the study conducted in the outpatient HIV treatment 
clinics in the academic hospitals associated with the University of the Witwatersrand, more 
frequently complained of numbness or tingling in their hands or feet and more often felt “I 
don’t look like myself” than the online survey in the UK(24).  Pain is a common symptom for 
this study and for other studies(10,17,19,23,24,40).  These and other symptoms all require 
adequate acknowledgement and assessment from the treating doctors, and then they 
require appropriate, acceptable and effective treatment.  Without such support and 
treatment, patients will continue to suffer from these symptoms.  Symptoms such as 
nociceptive pain, neuropathic pain, sadness and worry can escalate if untreated, leading to 
far greater morbidity for the patient, and a far more difficult clinical situation to manage. 
All four psychological symptoms (feeling sad, feeling irritable, worrying and feeling nervous) 
are in the top ten most prevalent symptoms in this study, with feeling sad being the most 
prevalent symptom overall.  The study in New York had very similar findings with regards 
these psychological symptoms(10), as did the studies in the UK(23,24).  The study in Uganda 












symptom and feeling sad was the 11th most prevalent symptom(17).  For the participants in 
the study in Soweto, a low mood was the fourth most common symptom, with 69.9% of 
participants experiencing low mood(19).  Makoae et al found in their study in sub-Saharan 
Africa that “fear and worries” as a symptom was in the top five symptoms in their study(20).  
These studies all highlight the high prevalence of psychological symptoms amongst patients 
with HIV which this study confirms.  It appears that these symptoms are under-recognised 
by health care workers in HIV treatment clinics and that there is inadequate holistice 
assessment for psychological symptoms, leading to poor psychological support and under-
treatment of psychiatric conditions and an ongoing cycle of psychological suffering. 
The high prevalence and high rating of high frequency for the psychological symptoms is 
one of the most notable findings on first looking at the prevalence and burden data.  The 
most prevalent symptom was feeling sad, with a high frequency.  Many other studies of HIV 
positive patients, some of which were mentioned above, have also reported a high 
psychological symptom prevalence and symptom burden(10,20,22-25,37).  Lampe reported 
from a study in London, that nearly half of their cohort of patients reported either anxiety or 
depression, with these patients having a significantly greater risk for rebound of the viral 
load, than those patients without anxiety or depression and that this risk was not 
adequately explained by poor adherence to HAART(72).  Can sadness be extrapolated to 
depression, and if so, should we be screening our patients for depression more routinely?  
Perhaps sadness, in conjunction with other symptoms such as worry, irritability, and even 
physical symptoms in otherwise HAART-responsive patients, can be linked to depression 
which should be treated?  There is of course the ever-present difficulty in using physical 
symptoms as markers for depression in patients with a general medical condition such as 
HIV.  How relevant is this for a clinically, virologically and immunologically controlled patient 
on HAART?  Rodkjaer et al remind us that patient self report of symptoms of depression is 
not adequate to diagnose a Major Depressive Disorder (MDD) and that a psychiatric 
consultation is the optimal manner in which to diagnose MDD(38).  However, their study 
also found that depression was underdiagnosed in their setting in Denmark with 38% of 
participant experiencing symptoms of depression and 26% being diagnosed with MDD(38).  
They also found that patients who had MDD (but had not been diagnosed or treated for 












that their study points to a link between depressive and physical symptoms and potential 
virological failure in the future, for patients who are currently virally-suppressed on 
HAART(37).  A study conducted by Sherr et al among an outpatient sample of patients in the 
UK found a concerning prevalence of suicidal ideation(73).  Suicidal ideation was found to be 
more frequent among patients with higher physical symptom distress and higher 
psychological symptom distress(73), showing more evidence for the need for the 
management of all symptoms and how this is highly important for the mental health of 
patients.  Suicidal ideation is understood to be a very important medical issue to manage 
timeously, effectively and to follow up adequately.  These studies show that it is vitally 
important to screen patients for any psychological symptoms, for depression and for 
suicidality, so as to manage these symptoms effectively and assist in the overall holistic HIV 
management for patients, particularly to prevent poor adherence or non-adherence to 
HAART and even virological rebound despite adherence.  The findings of these other studies 
add to the evidence found in this study that points to a real need for health care workers, 
and doctors specifically, to recognise that psychological symptoms are common and that 
psychological support and or medical treatment is often needed but not often openly 
requested by patients. 
The prevalence and distress associated with these four high prevalence psychological 
symptoms shows that even patients on HAART have significant psychological symptom 
burden and that, regardless of whether the patients can be classified as clinically depressed 
and in need of anti-depressant medication, they do need significant and ongoing 
psychological support.  This is particularly important for patients on HAART as this could 
potentially relate to adherence to HAART, a fact that is considered when initiating patients 
on HAART.  All four psychological symptoms can impact on daily functioning.  They can also 
all impact on the sense of hope, or lack thereof.  Hopelessness was not assessed in this 
study, but Vogl et al found that the degree of hopelessness was an independent contributor 
to the overall distress caused by symptoms, as measured by the MSAS-Global Distress 
Index(10).   
Numbness or tingling of hands and feet is the classical symptom for neuropathic pain due to 
peripheral neuropathy.  In this study, this symptom was highly prevalent and highly 












prevalence of neuropathic pain(12-14,17,20,22,24,25,33,48).  Vogl et al found a similar 
prevalence of neuropathic pain to this study, but with a somewhat lower rate of high 
distress(10).  HIV itself is known to cause peripheral neuropathies, as do many of the drugs 
used to treat HAART.  Stavudine is the most likely drug of the commonly used ARVs to cause 
peripheral neuropathy and neuropathic pain(74) which was the second most frequent 
symptom to be perceived as due to HAART by the participants and also the second most 
common reason for a change in HAART.  Lamivudine and didanosine are the other drugs 
most likely to cause peripheral neuropathy(74).   
Many patients subjectively felt that their peripheral neuropathy was due to their HAART 
which may be correct as it is a known side-effect of certain antiretrovirals.  As this is a 
subjective view, the objectivity of this view may be questioned but it is interesting to note 
that there may possibly be a great deal of negative emotion towards HAART which may be 
seen as causing problems.  This could relate to inadequate initial and ongoing education 
around HIV, AIDS and HAART.  Very importantly it could also point towards inadequate 
support and management of symptoms, once HAART is started and patients are more 
clinically stable.  These issues could all result in poor treatment adherence.  Causality can 
not be established on the basis of this subjective question and the specific answers which 
participants gave, but it is an important principle of communication that the health care 
worker should listen to their patient and specifically address the concerns the patient may 
have and also the symptoms they are experiencing.  Shared decision making is the most 
favourable method of conducting the decision making process in a consultation, as it 
enables the patient to voice their opinions, feelings and beliefs; and for these to be heard 
and acknowledged and appropriately addressed by their health care worker(75).  This leads 
to the patient understanding more about their medical management and so feeling more 
satisfied with their medical care(75) and therefore supporting adherence on the part of the 
patient.   
The lack of symptom control for the neuropathic pain experienced by the participants in this 
study suggests that there is under-treatment of neuropathic pain in these treatment clinics.  
This is surprising, given the recognition that neuropathic pain is a complication of HIV 
disease and a side effect of some ARVs.  It suggests that patients are not adequately 












accepted treatments for neuropathic pain which also require regular review of the adequacy 
of the pain management.  The findings point to the need for HIV clinicians to have more 
training in the assessment and management of neuropathic pain.   
Harding et al found that in their sample of online patients in the UK, patients who were on 
HAART had a significantly greater prevalence of numbness or tingling than those who were 
not on HAART(24).  A reason that the prevalence of neuropathic type pain is so high 
amongst the participants of this study of the three outpatient HIV treatment clinics, could 
be that vast majority of the sample were on HAART and just less than half had changed 
HAART regimens at least once.  The drugs that participants were taking reflect the 
guidelines for HAART treatment in the South African public health sector(4,5).  Some 
authors have discussed that once patients have changed HAART regimes, there appears to 
be a higher prevalence of overall symptoms, including of neuropathic type pain(11,24).  
Neuropathic pain is a frequent reason for the change of a HAART regime so it is of concern 
that patients who have already changed HAART, may continue to experience neuropathic 
pain despite the change in HAART.  Clinicians working at HIV treatment clinics need to be 
aware of this so that the necessary vigilance for the symptom can be employed, to ensure 
that patients do not go un-treated or under-treated. 
The prevalence of nociceptive pain in these study participants was also high, with a 
symptom burden showing a large proportion of participants experiencing high distress from 
their pain.  One London-based outpatient study found a very similar prevalence for pain(23).  
Pain amongst patients with HIV has been widely studied and described.  There are many 
possible pain syndromes that can be encountered among patients who are HIV positive(12).  
In our study, no distinction was made on sites or type of pain, as the main aim was to first 
assess prevalence and overall burden of pain in general in this population.  In a study of 
AIDS outpatients in New York City before 1996, using the MSAS-SF together with other 
tools, the prevalence of pain was even higher(10).  Wakeham et al found the prevalence of 
pain amongst newly diagnosed HIV positive patients to be similar to the study in New 
York(17).  Both these studies had different study populations to our study but both used the 
MSAS-SF.  In a study of patients with very advanced AIDS at a hospice in Johannesburg, the 
majority of patients experienced pain(19).  This population is also different to our study as 












all those patients had had access to HAART.  In the current study of the patients attending 
three HIV treatment clinics in Johannesburg, the majority of study participants were on 
HAART as an outpatient at the time of study.  It may therefore appear that HAART can 
facilitate a reduction in the development of pain as a part of the prevention of progression 
of disease.   However, no comparisons can be drawn between the studies.  This needs to be 
studied formally in a longitudinal manner because an online cross-sectional survey 
conducted in the United Kingdom, amongst HIV positive gay men, found the opposite to be 
the case – namely that the prevalence of pain amongst those patients on HAART was very 
similar to the prevalence of pain in this current study, but the prevalence of pain in those 
not currently on HAART was lower, suggesting that HAART may be responsible for an 
increasing pain prevalence(24).  Norval et al in the Pain Management chapter, of A Clinical 
Guide to Supportive and Palliative Care for HIV/AIDS in Sub-Saharan Africa, summarize some 
of the findings from previous studies, pointing out that the pain experienced is diverse and 
can commonly be linked to marked psychological symptomotology, as well as functional 
changes(76).  The findings from this study show that patients who reported the presence of 
pain, regardless of the pain distress rating, had statistically significant greater psychological 
distress (as per the MSAS-PSYCH scores).  It is interesting to note that the top 6 most 
prevalent symptoms found in this study include pain, numbness or tingling in hands and 
feet, feeling sad, feeling irritable and worrying.  These symptoms also have all been shown 
to have high distress or high frequency in this study, so the overlap is possibly more than co-
incidental.  This warrants further future study in this particular context as previous 
international studies have shown a relationship between the presence of pain and 
depressive symptoms(44,77).  The symptom that occurs first is uncertain, but it seems likely 
that uncontrolled pain can result in psychological distress, including symptoms of 
depression.  The IASP definition of pain makes it clear that pain is a symptom that involves 
the physical as well as the psychological in its expression and experience(41), so it is also 
possible, that patients who have symptoms of depression are likely to experience any pain 
they may have, as more severe than patients who do not have symptoms of depression.  
These findings again point to the need for the “impeccable assessment and treatment of 
pain and other problems, physical, psychosocial and spiritual” according to the WHO 
definition of palliative care(6).  Dame Cecily Saunders introduced the concept of total pain 












described the all-encompassing nature of the pain experience – pain is experienced in the 
physical, emotional, social and spiritual spheres and pain is influenced by all four of these 
areas(76).  Therefore, it is not unexpected to find that in this patient group, patients who 
experienced pain also had higher rates of psychological distress.  Palliative care advocates 
that for this kind of pain to be effectively managed, the physical component of the pain 
should be adequately managed and that following this, the psychological sources and 
aggravators of pain should all be addressed(76), and management should be provided in a 
holistic and individualised manner.  Total pain also requires that social and spiritual sources 
and aggravators of pain be sought, assessed and managed appropriately, to complete the 
holistic management of the patient’s pain experience.  This management of total pain 
requires knowledge of the physical pain assessment, as well as an adequate knowledge 
regarding the prescribing of analgesic drugs and how to titrate these drugs effectively, 
according to pain levels.   
These study findings suggest that pain is generally poorly assessed and also poorly managed 
amongst these patients receiving outpatient HIV management.  The prevalence of pain of 
high distress suggests that clinicians are not aware of the possibility that their patients may 
be suffering from pain, or if they are, that they do not have the skills and training required 
to assess and to treat pain adequately.  This suggests the need for training of HIV clinicians 
in pain management and in palliative care so that their patients can benefit from adequate 
and durable pain control. 
The symptom “I don’t look like myself” was also prevalent and interestingly it was the most 
highly distressing symptom overall, if it was present.  The study did not ask for any further 
detail from participants, regarding what they meant by this phrase.  Therefore the meaning 
of this symptom for the participants can only theoretically explored.  It could be 
extrapolated that for some patients this could involve lipodystophy or fat redistribution 
changes, which was commonly named by patients as a symptom that they felt was due to 
HAART.  Stavudine, Zidovudine and Lopinavir-Ritonavir (as well as other protease inhibitors) 
cause lipodystrophy (fat redistribution from face, buttocks, legs and arms to the back of the 
neck, abdomen and breasts)(74) which was the most common ‘symptom’ due to HAART of 
which the participants complained and also the most common reason for a change in 












Skin changes are often seen in HIV positive patients, and can be the first signs of disease.  
They may be held as very significant by patients in the way their bodies change due to the 
disease.  Rashes causing skin changes occur with efavirenz, atazanavir and particularly with 
nevirapine(74).  Skin changes were the fourth most common symptom attributed to HAART 
by the participants, and can clearly also be a drug side effect.  However, more patients 
identified the symptom of “I don’t look like myself” than those who identified skin changes, 
and so it appears that skin changes are not the only means by which patients judge their 
change in appearance.  Swelling of arms and legs was not markedly prevalent, but if it was 
present, it had a high distress rating, and so appears that it could be a contributing factor to 
the feeling of “I don’t look like myself”.  Weight loss was a fairly prevalent symptom with a 
high distress rating, and so is quite likely to have contributed to the feeling that the 
participant does not look like him or herself.  It is interesting to note that patients describe 
weight loss, despite many of them being on HAART.  Hair loss was not a prevalent symptom, 
but it did have high distress if it was present.  All of these symptoms could contribute to the 
participants feeling that they did not look like themselves.  A person’s self-image is highly 
personal and maybe be vulnerable to changes in internal and external factors.  Whatever 
the reason for the patients feeling that they did not look like themselves, the effects of this 
symptom can be far reaching and very debilitating to the individual.  Does this feeling relate 
to a confusion in the person’s identity?  Do they act differently as a result of feeling this 
way?  Is this feeling associated with the societal stigma they may experience in relation to 
the diagnosis of HIV?  Does this feeling relate to the overall disease and symptom 
experience that these patients experience internally on a daily basis?  If any of these issues 
do stem from the symptom “I don’t look like myself”, it appears likely that this overtly 
physical symptom does have direct links to psychological symptoms, translating into feelings 
of “I don’t feel like myself”, opening up many doors of vulnerability and creating reasons for 
debilitating emotional distress.  The inter-relatedness of the physical and the psychological 
aspects of a person’s being are widely acknowledged and accepted by palliative care 
practitioners(6), and training in assessing and managing problems in both of these areas 
would benefit HIV clinicians and their patients alike. 
“Problems with sexual interest or activity” was a highly prevalent and highly distressing 












HAART.  Two UK-based studies found very similar prevalence of this symptom(23,24), as did 
the New York study(10), while the while the study in San Francisco found a smaller 
prevalence(25).  This symptom highlights how invasive this disease is into the relational lives 
of patients.  Sexual intercourse is the most frequent transmission route for HIV in South 
Africa(3).  This fact of transmission may be a potential cause for the HIV positive person to 
suffer psychologically in relation to the area of sexual intercourse, and thus have 
psychological problems with sexual interest or activity.  HIV is associated with other sexually 
transmitted diseases and so there may also be associated physical factors for the individual 
that are involved in the symptom of problems with sexual interest or activity.  In the Soweto 
Hospice study, women had more genital sores and more genital pain than men(19).  The 
study in the three HIV outpatient clinics at the academic hospitals attached to the University 
of the Witwatersrand did not stratify between men and women in this area of problems 
with sexual interest or activity.  If sexual activity is impaired there may be relationship 
problems and hence more psychological symptom prevalence and distress.  Wilson et al 
reported that women with HIV had less satisfaction with sexual function than those who 
were not HIV infected, and that symptoms of depression, and CD4 counts under 200 were 
also related to poorer sexual function(78).  Body image has been shown to be altered, as the 
symptom “I don’t look like myself” is highly prevalent and distressing to patients.  This could 
also affect the patients own view of their gender role and so affect intimacy and physical 
sexual expression.  Patients have particular needs in this area of their lives, requiring far 
more support and even treatment than they do currently receive but what kind of support 
would be appropriate requires further research. 
The constitutional symptoms such as lack of energy, sweats, weight loss and feeling drowsy 
are all fairly prevalent and have high distress ratings.  Albumin has been found to be good 
indicator of morbidity in advanced disease in general, but not necessarily specifically in HIV 
disease(79,80).  Morbidity relates to the suffering experienced by the patient, and so could 
include symptoms and the burden of symptoms experienced by patients.   Albumin has also 
been found to be a predictor of mortality, with a low albumin predicting decreased 
survival/poorer prognosis and increased risk of complications(79,80), which also relates to 
symptom prevalence and the burden from symptoms.  Albumin itself has been found not to 












nutritional status of patients from the albumin results obtained from the participant files.  In 
this study albumin levels did not correlate with symptom prevalence or distress.  So the use 
of albumin as a prognostic indicator for symptoms does not appear to be of any value 
according to this small sample.  The relationship between albumin levels and the symptom 
profile would have to be formally researched for more generalisable conclusions to be 
drawn.  These findings further add weight to the notion that laboratory values are not 
indicators of the disease experience of patients with HIV, reminding us that a good history 
enquiring about symptoms and their burden is of pivotal importance in managing all 
patients with HIV disease. 
Bekker and Adams point out that, although constitutional symptoms “are not usually life 
threatening in themselves, they may be significant factors eroding a patient’s comfort and 
quality of life”(81).  Feeling drowsy and difficulty concentrating had fairly similar rates of 
prevalence and difficulty in concentrating had only a marginally higher percentage of high 
distress.  These symptoms may well be linked to each other, and to difficulty in sleeping(25).  
Difficulty in concentrating is included in the MSAS-SF Psychological Symptom subscale so 
this symptom could also be related to the psychological symptoms, and if depression is 
present, this may also of course impact on the symptoms of feeling drowsy, lack of energy 
and lack of appetite.  Lee at al emphasise the importance of sleep and its relationship to 
energy levels and symptoms in general(25).  In Palliative Medicine, patients are always seen 
as a whole – physically, psychologically, socially and spiritually(6).  The interplay between 
these symptoms is therefore highly relevant.  Cause and effect can only be speculated upon, 
as this was not the focus of this particular study, however it seems likely that HIV clinicians 
would benefit from training in the palliative approach of assessing the patient holistically so 
as to identify the physical and psychological symptoms as well as the social and spiritual 
problems that may exist and be impacting on the patient’s overall disease experience.  This 
would result in more holistic and comprehensive management plans for patients and as 
such benefit their overall quality of life.  
Constitutional symptoms may be related to HAART side-effects, such as hyperlactaemia 
which is known to be caused by abacavir, didanosine, lamivudine, stavudine, zidovudine, 
tenofovir(74).  Metabolic changes, such as hypercholesterolaemia, hypertriglyceridaemia 












drugs used can cause some of the symptoms found to be a problem for participants, but 
HAART can not account for all the symptoms, and even if it could, there would still be every 
reason to treat the symptoms symptomatically for patient relief from suffering and for their 
quality of life.  Clinicians should be aware of the effects of the drugs they are prescribing, so 
as to adequately manage these side effects, including the palliation of those symptoms that 
are not easily avoidable. 
It is known that TB is a significant and frequent opportunistic infection amongst HIV infected 
people in South Africa.  It was of interest to assess whether TB has any influence on 
symptom prevalence or burden, however not enough information was gathered regarding 
the timing and nature of the TB diagnosis to be able to make adequate associations, and the 
only information we had available to use did not show any association of the influence of TB 
on the illness experience.  Active TB infection does produce significant symptoms, and these 
should be treated by first treating the cause, with the appropriate antibiotic regimen for TB, 
while simultaneously actively managing the unpleasant associated symptoms that the 
patient may experience, such as coughing, fevers, chest pain and dyspnoea(82).  It is not 
sufficient to just treat the cause and hope that the symptoms disappear fast enough to 
improve the patient’s problems.  Active palliation of the symptoms caused by active TB 
should be a part of the management plan of the patient. 
The gastro-intestinal symptoms of feeling bloated and constipation were more prevalent 
than diarrhoea.  The two studies based on patients in the UK found more diarrhoea than 
constipation and diarrhoea had a reasonably high prevalence rate in each of those 
studies(23,24).  Historically, and in the pre-HAART patient, diarrhoea was a significant 
symptom for HIV positive patients, and so it appears that HAART may do more than just 
protect against diarrhoea but may be related to constipation in some way.  However, 
bloating and constipation are usually multi-factorial and may be more related to diet and 
lifestyle than to HAART.  These symptoms are all readily managed by clinicians trained in 
symptom control and palliative care, motivating again for the need for HIV clinicians to be 
trained in palliative care.   
These results suggest that symptoms are prevalent and should be extensively and actively 












purely on the CD4 count, WHO stage, presence of opportunistic infections and whether or 
not HAART is being taken(14).  The very important area of HAART adherence is a focus for 
HIV outpatient treatment clinics in the management of their patients.  The findings of the 
symptom prevalence and burden of the participants in the three clinics sampled for this 
study, together with the evidence from the literature that points to the integral link 
between symptom experience and HAART adherence(31,37,38) and are evidence for the 
need for the holistic management of patients with HIV in outpatient HIV treatment clinics.  
This holistic management must include specific palliation of symptoms during each 
scheduled clinic assessment, requiring HIV clinicians to be adequately trained in palliative 
care and actively delivering appropriate symptom control.  In their review of the state of 
palliative care in sub-Saharan Africa, Harding and Higginson comment that there is little or 
no involvement of palliative care directly within and with HAART treatment clinics, and that 
should this happen, it would offer significant benefit for patients and providers alike, as 
there is much evidence from the developed world that HAART and palliative care are not 
and should not be mutually exclusive(83).  
 
MSAS-SF Subscales 
The Cronbach’s coefficient alpha for MSAS-GDI, MSAS-PHYS, MSAS-PSYCH and for the 
TMSAS prove the reliability of the subscale scores in this study.  The Cronbach’s alpha 
coefficient for the constitutional symptom subscale showed that this is an unreliable 
subscale.  The constitutional symptom subscale is new and was not validated, and as the 
Cronbach’s coefficient alpha shows it is not reliable, no significance that can be attributed to 
this score, other than to say that it appears to be invalid. 
The mean global distress (MSAS-GDI) score is similar to that of the study conducted among 
HIV positive outpatients in London(23), showing a somewhat lower global distress than in a 
few of the already mentioned international studies which used the MSAS-SF tool(10,17,24), 
but it is higher than the MSAS-GDI score in a study done in San Francisco in the USA(25).  
Never the less, the score indicates a high degree of untreated global distress, which 
incorporates both physical and psychological symptom distress.  This distress rating shows 












experience, motivating for a greater emphasis on the holistic management of the patient, as 
indicated by the definition of palliative care(6).   
The mean physical distress (MSAS-PHYS) score was again very similar to that found for the 
study of the outpatient population in London(23).  Two of the other studies compared, had 
higher mean physical symptom distress scores than this(10,17), while two had only slightly 
lower mean physical distress scores(24,25). Of the two studies with higher scores, one was 
conducted on a sample of patients at diagnosis, pre-HAART in Uganda(17), and for the 
other, little information was given on antiretroviral use by the patients, and it was done 
before protease inhibitors were available(10).  This shows that the cohort for this study 
experienced what is considered in the literature to be high degrees of physical distress.  
Measureable physical symptoms have been shown to be more commonly recognised by the 
physician(18), but even so, the findings of this study suggest that physical symptoms are not 
adequately recognised, assessed, or managed in these HIV treatment clinics, leaving the 
patient with unmanaged physical suffering.  
The mean psychological distress (MSAS-PSYCH) score was again very similar to the score for 
the study on the outpatient population in London(23), showing that a large amount of 
psychological distress was experienced by the participants of this study.  Like the MSAS-
PHYS score, this MSAS-PSYCH score is higher than two other studies(17,25) and lower than 
the score for the online survey done in the UK(24) and for the study done in New York(10), 
concluding that the psychological symptom distress is unacceptably high and even higher 
than the  physical symptom distress.  Clinicians at the HIV treatment clinics surveyed appear 
not to be assessing psychological symptoms or if they are assessing them, it appears that 
they do not have the tools with which to manage psychological symptoms, resulting in the 
patients experiencing high degrees of distress in this area. 
The mean total symptom distress (TMSAS) was not often reported in the literature but for 
the one study that did report this score it was lower(25) than this current study conducted 
in the three HIV treatment clinics in Johannesburg, showing that the participants in this 
study experienced large distress from their total number of symptoms.  This again suggests 
inadequate assessment and management of symptoms at these HIV treatment clinics, 












These symptom distress scale correlations with the biological markers of HIV disease, 
namely CD4 count and viral load, and with the WHO stages of disease and the KPS score, 
show some trends to guide clinicians.   Symptom prevalence and distress was not found to 
correlate with viral load results, nor with CD count groups.  The viral load was not found to 
be predictive of any of the symptom distress subscales.  Similar to the findings of Lee et 
al(25), this study did show that on multiple regression analysis, the latest CD4 count was 
predictive of physical symptom distress as rated by the MSAS-PHYS.  However there was not 
a lot of weight assigned to the latest CD4 count as a predictor in this regard.  The finding 
that viral load results are not related to symptom prevalence, is consistent with the findings 
from at least one other study(24).  Lee et al found that global symptom measures were not 
related to viral load results but that in overall regression analysis, a detectable viral load did 
contribute to the change in symptom number(25).   
WHO staging is the indication of how advanced the HIV disease was at diagnosis and is 
clinically important for the management of HIV disease, and gives the clinician a quick 
roadmap of what may have preceded a particular patient’s disease pathway.   The WHO 
staging was delineated when CD4 counts were not readily available in resource constrained 
settings, enabling clinicians to manage their patients in a clinical framework where no 
laboratory results were available.  This current study found that there are significant 
differences for MSAS-PSYCH and MSAS-GDI and there are also differences for MSAS-PHYS 
when WHO stage 1 is compared to any other WHO stage.  There was no significant 
difference between WHO stage 2, 3 or 4 for the MSAS-SF subscales.  This shows that 
symptom distress is a greater problem for patients who are staged as WHO stage 2, 3 and 4 
as compared to those staged WHO stage 1.  However, patients in WHO stage 1 do 
experience symptom distress.  These findings for WHO stage in relation to symptom distress 
were confirmed in multiple regression analyses.  Wakeham et al found that in their sample 
of newly diagnosed patients in Uganda that the WHO staging was not an indicator of 
symptom prevalence or burden(17).  Two other international studies did find that those 
patients with AIDS-defining conditions (which is the same as WHO stage 4 disease) did have 
more symptoms and greater symptom distress than those without AIDS-defining 
conditions(10,25).  As for the findings for viral load levels and CD4 ounts, symptoms are 












presumed to be without symptoms based purely on the laboratory markers or WHO stage. 
This calls for a patient centred, palliative care approach to be employed by all health care 
workers who are involved in any management of HIV positive patients.  Palliative care can 
be provided by the trained health care worker in the HIV treatment clinic where the patient 
receives their HIV care thereby reducing the need for the patient to attend another clinic 
which would only add an extra burden to the patient who already has many problems to 
face.   For palliative care to be effectively provided by HIV treatment clinics, all health care 
workers, but particularly the doctors at the clinic, need to have the necessary accredited 
training to equip them to palliate their patients effectively. 
This study has also found that symptom distress is correlated with functional status as 
measured by KPS.  All symptom distress measures (global, physical and psychological 
symptom distress) were significantly higher for patients with KPS scores below 100%.  The 
majority of participants had a KPS score of 90% which is a relatively high functional status 
and means that these participants were able to carry out normal activity but according to 
the findings of this study, these patients had significantly greater symptom distress than 
patients with a normal KPS of 100%.  Multiple regression analyses showed that the KPS 
score and particularly KPS 40-80% was predictive of physical, psychological and global 
symptom distress.  Vogl et al also found a relatively high functional status for their sample of 
patients, with 80% of their sample functioning at KPS 70% or above(10), while Del Borgo et 
al found a mean KPS of 70% in their sample(46).  In validating the MSAS-SF, Chang et al 
found that KPS functional levels correlated well with changes in the MSAS-SF subscales for 
cancer patients and said that: “The KPS is valuable for prognosis, but does not indicate what 
steps the practitioner can take to help patients with poor performance status”(64).  They 
suggested therefore that symptom assessment tools are clinically useful together with the 
KPS, so as to assist the clinician in how to symptomatically manage and assist a patient with 
a poor functional status(64).  The findings of this study re-affirm the link between a poor 
functional status and symptoms and the need for symptomatic intervention.  However, 
what is also clear is that patients at all levels of functionality have symptoms and also that 
function may be affected to a relatively small degree (for example, with a KPS of 90%) with a 
significant increase in symptom distress.  This calls for the clinician to have a low threshold 












patients, regardless of how well they may appear to be functioning.  A high KPS does not 
rule out the possibility of the presence of symptoms for the patient, and as Chang et al point 
out(64), the information from symptom assessment tools is of more practical value for the 
palliation of the patient’s symptoms that the functional status itself.   
The initial CD4 count was obtained for the majority of participants.  The mean CD4 count 
before starting HAART reflects the South African national guidelines prior to 2010, for 
HAART to be started once a CD4 count went below 200 cells/mm³(5).  However, initial CD4 
count was well under 200 cells/mm³ reflecting a tendency amongst South Africans to 
present quite late in the progression of HIV disease.  Voluntary counselling and testing (VCT) 
is available but many patients have found the barriers to the use of VCT sites to large to 
overcome so that they will just wait until they may get sick before getting tested for HIV(3).  
This is an important challenge to address now that HAART treatment is recommended once 
the CD4 count drops below 350 cells/mm³(4).    
All patients had a latest CD4 count with a mean CD4 count value that reflects the improved 
immunological status of the patient on HAART, as the majority of the participants were 
taking HAART.  The relevance of the viral load result or the CD4 count result on the patient 
experience of their daily life is not as obvious to them as the frequency of their symptoms 
and the burden their symptoms impose each day.  If this is what affects our patients’ daily 
lives, surely our focus as health care workers should be on the patient and their disease 
experience, rather than their laboratory results, as important as these may be for their 
management.  This should be the case, as the findings from this study show that patients 
experience symptoms with a high degree of distress, regardless of their CD4 count or viral 
load level.  This finding is echoed by other studies, showing that patients can have 
significant symptoms and symptom distress, at any CD4 count level(10,17) although Harding 
et al found that the latest CD4 count did relate to the MSAS-GDI score(24) and Lee et al 
found that although the CD4 count was not directly linked to symptoms, patients with a CD4 
count of under 200 did have higher MSAS-PHYS scores(25).  These findings highlight the 
importance of assessing for symptoms and the burden and distress caused by these 
symptom, regardless of the CD4 count, as the CD4 count has been shown to be generally a 
poor marker for symptom prevalence and burden.  Palliative care is able to address these 












spiritually(6) and so being able to make a management plan that is patient-focused, with 
excellent symptom control and psychosocial and spiritual support as is required by each 
patient.   
The findings of this study indicate that while HAART is very effective in controlling the virus 
and allowing restoration of immune function and thus clinical improvement for the patient, 
HAART does not prevent symptoms from occurring in large numbers and does not prevent 
high degrees of burden of physical symptoms, nor high frequency of psychological 
symptoms.  This shows the large and ongoing need for symptom management and palliative 
care in HIV treatment clinics even in, and especially in, the era of HAART.  As discussed in 
the literature review, a number of studies have shown that symptoms and distress from 
symptoms are correlated with decreased HAART adherence(31,38,55) and even with 
virological failure on HAART that is largely independent of adherence to HAART(37).  This 
shows the large and pressing need for routine, appropriate, accessible and adequate 
symptom management and palliative care in the HIV treatment clinic for all patients who 
are on HAART.  Approximately three quarters of the participants with a latest viral load 
exhibited viral suppression at last check.  In the light of evidence from the 
literature(31,38,55), it is possible that this finding of inadequate viral suppression on HAART 
is related to poor adherence, which could be due in part at least, to the high prevalence and 
distress of psychological symptoms and the relatively high global distress score amongst this 
group of patients.  This is of particular concern as Lampe et al found that physical symptoms 
and symptoms of depression can point towards future virological failure on HAART, even 
possibly independently of poor adherence(37).  If psychological symptoms that are 
unmanaged can cause such far reaching consequences as treatment failure from lack of 
HAART adherence, this is of great concern for the HIV clinician and again is a motivator for 
the urgent need for adequate psychological support and management of psychological 
symptoms for all patients with HIV, in a manner that recognises that holistic care is 
individualised care according to palliative care principles.  Palliative care recognises that this 
care involves a journey with the patient along their path of life, assessing regularly and 
managing symptoms actively and holistically. 
Another finding of this study is that a change in HAART was found to be predictive of an 












degree of life stress, as the reason for the change may involve significant symptoms and 
may even involve hospitalisation if severe.  The change itself may invoke psychological 
distress, such as fear and worry regarding the success of the new medication.  All of these 
psychological symptoms require palliation so as to assist the patient in coping with this 
stressful life event while at the same time, palliative management of the physical symptoms 
relating to the failure of HAART is of great importance in relieving the physical suffering of 
the patient.   
The majority of participants answered “yes” To the subjective question “Do you think any of 
your symptoms are because of your ARVs?”  This indicates that ARVs could in themselves be 
burdensome to patients, either psychologically or in actually causing physical symptoms, as 
this is the subjective opinion of the participants who do take HAART.  The finding that 
participants with an undetectable viral load do often blame their HAART for their symptoms, 
according to the subjective question asked, is of concern in and of itself, particularly with 
respect to future treatment adherence.  Body fat distribution changes and numbness or 
tingling of hands and feet were the two most common symptoms that were attributed to 
HAART by patients.  These do relate to the common side effects that are known to be due to 
HAART drugs(74).  Regardless of what the cause of symptoms may be, it is important to 
address each of these symptoms with explanation and with appropriate pharmacological 
and non-pharmacological palliative management in a patient specific manner.  
Communication between the patient and the doctor is the basis for a sound assessment of 
the patient experience of their disease and gives the clues to what suffering the patient may 
be experiencing.  In the often disempowered and vulnerable population group that this 
study sampled, patients may not voice concerns unless they are specifically asked about 
their concerns, their beliefs and their symptoms.  Without this knowledge of their patients, 
clinicians will not assess problems accurately and therefore symptoms and suffering will go 
untreated.  Palliative care principles enable the clinician and health care worker to come 
alongside their patients to make accurate assessments and so be able to manage symptoms 
effectively.  If symptoms are very troublesome for patients and these symptoms are not 
addressed and managed by their doctor or relevant health care worker, there is a possibility 
that the patient may decide to stop taking the HAART.  Severe and debilitating symptoms 












that he is alone in his walk along the pathway of his life, with no real assistance from the 
medical personnel who are treating his disease.  The patient may then start to make his own 
decisions regarding his HAART and these decisions will likely be based on his own beliefs 
about his disease and about the medication he is taking, rather than based on the education 
and guidance received from the foundation of a good doctor-patient relationship(75).  
Palliative care operates with the principle that excellent clinical care comes out of a 
relationship of trust between the health care worker and the patient.  On this basis, the 
patient should not feel abandoned and will be able to address his concerns with his doctor, 
allowing adequate discussion and subsequent palliation of the distressing symptoms and 
therefore increased compliance on HAART.    
The trend of the findings for the MSAS-SF subscales of this study are similar to other studies 
conducted on different population groups where many of the population have been 
diagnosed for some time and are on treatment for their disease, whether or not HAART has 
started as of yet or not – the trend seems to be that the physical symptom distress is less 
than the global distress and that the psychological distress is the most distressing of 
all(10,23-25).  Fontaine et al found that physicians most correctly identified symptoms that 
were related to measurable physical signs but were definitely less reliable in identifying 
symptoms that were not readily measurable(18), showing the need for vigilance in enquiring 
about symptoms routinely for each patient and specifically for enquiring about 
psychological and less obvious physical symptoms.  In a study amongst patients with cancer 
who were already receiving palliative care in South Africa and Uganda, the MSAS-SF 
subscale scores were higher for physical and global distress but similar for psychological 
distress(71).  Vogl et al also found that AIDS outpatients and cancer patients had similar 
symptoms with AIDS patients actually experiencing more symptoms than the cancer 
patients used as a comparison(10).  The findings that patients with HIV and patients with 
cancer have similar symptom prevalence and burden from symptoms, are further evidence 
for the need for symptom control and palliative care to be incorporated into the general HIV 
outpatient treatment clinic management of patients.   
The MSAS-SF subscale scores in this study suggest that the symptom distress experienced by 
the cohort of this study is similar in all the categories (global, physical, psychological) to that 












the results of this study to the London based study are further evidence that patients with 
HIV who attend HIV treatment clinics and are on HAART do experience a large number of 
symptoms from which the symptom burden is marked.  The similarities of the findings give 
further motivation for the need for symptom control and palliative care to be urgently 
incorporated into HIV treatment clinics in South Africa.  Palliative care aims to “improve the 
quality of life of patients and their families facing the problems associated with life-
threatening illness”(6).  HIV disease remains a life-threatening disease even with HAART and 
as this study shows, symptoms occur frequently and with high degrees of distress and 
symptom burden.  Symptoms are one of the components of the assessment of the quality of 
life of patients(28-30) and as such it is not possible to improve the quality of life of the 
patients at these HIV treatment clinics unless symptoms are “impeccably” assessed and 
managed(6).  The symptom distress shown in this study motivates for palliative care to 
become routinely incorporated into the management of each patient attending the clinics, 
so that all patients benefit from improvements in their quality of life through adequate and 
ongoing symptom control.  The aim of good quality of life for their patients, through the 
palliation of symptoms and suffering, is a very important aim for clinicians to pursue for all 
their patients who have a good life expectancy on HAART, not just for those patients whose 
life expectancy is imminently limited by their disease. 
 
Limitations 
This study was of a cross-sectional design and therefore no causality between the 
relationships can be established.  The sampling method may be the biggest limitation of the 
study as convenience sampling may introduce selection bias.  True random sampling was 
not possible in the clinic environment, and therefore to minimize bias, every 5th eligible 
patient was invited to participate.  Selection bias was also involved due to the type of 
patient who attends the HIV clinics.  Those patients unlikely to have attended the clinic (and 
thus excluded from the study) were those who did not know their HIV status, those who 
were too ill to go to the clinic, those who would not attend the clinic because of stigma, and 
those patients with a medical aid or who can afford to receive HIV management privately.  
Patients with HIV disease who were admitted to hospital due to complications or 












study to sample patients attending the specific HIV treatment clinics described so the 
exclusion of hospitalised patients was anticipated and is accepted.  No clinical data was 
collected on patients who did not choose to participate in this study and therefore it is not 
known if and how these patients differed from the participants of the study in any way. 
Another potential limitation of the study was the participant understanding of the MSAS-SF 
but I believe this was satisfactorily improved by the translation of the MSAS-SF and by using 
an interviewer administered technique.  The translated MSAS-SF was however not formally 
validated prior to use in this study.  Another area for potential bias was participant 
acquiescence to the interviewer asking the questions.  Therefore the research assistants 
were trained appropriately and they did in fact have significant previous experience in 
research work to be aware of this danger. 
A number of participants who were staged as WHO stage 2 did have previous diagnoses that 
could have classified them as stage 3 (and for some, even as stage 4); however it is not 
known at which point in time these diagnoses were made.  The WHO stages that were being 
assessed in this study were therefore the stages that the treating clinicians would find in the 
clinic file and would be assumed to be the WHO stage at diagnosis.  However, it may have 
been that patients were initially incorrectly staged as WHO stage 2 while actually being of a 
higher stage.  These discrepancies are not known to be the case but this would have caused 
an incorrect interpretation of the data analysis for symptoms relating to the WHO stages, 
but not to any other of the analyses. 
This study did not make any social or family support assessment or a financial means 
assessment.   Food security was not assessed and neither was there a nutritional 
assessment made.  There was also no assessment of the level of education achieved by the 
participants.  While it was not part of the aim and objectives of this study to research these 
variables, any of these variables may have confounded the relationships studied, as has 
been found by other authors in the Southern African and international literature(10,20,22).  












Conclusion of findings 
This study has found that, among HIV positive patients who attend outpatient HIV 
treatment clinics in Johannesburg, South Africa, the symptom prevalence is high and similar 
to the findings of a study conducted amongst HIV outpatient clinics in the UK(23).  The 
prevalence and burden of physical symptoms is high and the prevalence and burden of 
psychological symptoms is particularly high.  The most prevalent symptom overall was 
“feeling sad”, while the most prevalent physical symptom was “numbness/tingling in hands
and feet” showing a high prevalence of neuropathic pain in comparison to other studies(12-
14,17,20,22,24,25,33,48).  Pain was the 6th most prevalent symptom. The vast majority of
the participants were on HAART so it is clear that patients on HAART do experience 
symptoms and that these are highly burdensome and appear to be largely untreated, 
although symptomatic management was not specifically assessed. 
The majority of the patients surveyed were relatively well functioning with the majority of
KPS scores being 90% or 100%. Even these relatively well functioning participants had a 
large symptom prevalence and symptom burden. Symptom distress differences by CD4
count groups and viral load groups were not significant although the latest CD4 count was 
found to be predictive of physical symptom distress, as has been found by Lee et al(25) in
their study in the USA.  Although participants who were classified as WHO stage 2, 3 &4 did
have significantly more symptoms than participants staged as WHO stage 1, participants in
all four WHO stages had a large number of symptoms with associated high symptom
burden. 
The findings of this study suggest that symptoms and the distress generated by the 
symptoms can occur at any time in the course of HIV disease and that this phenomenon is 
multi-factorial.  The findings point to a high level of unmet symptom control needs.  
Symptoms are under-appreciated and under-assessed for a number of reasons which may 
include the business of the clinic and the time pressure the health care workers work under.  
These unmet needs also point to a lack of appreciation by health care workers for the large 
potential for patients to experience symptoms at any CD4 count, at any WHO stage and 
even for patients on HAART.  It is believed that this study does add to the evidence showing 
that symptom prevalence and symptom burden is high for patients attending outpatient HIV 












assessed as often as they visit their clinic.  Symptom management and palliative care should 



















Conclusion and Recommendations 
 
Conclusion 
The aim of the study was to assess the prevalence and burden of pain and other symptoms 
amongst the population of patients attending three outpatient HIV treatment clinics in 
three academic hospitals in Johannesburg, namely the Charlotte Maxeke Johannesburg 
Academic Hospital, the Chris Hani Baragwanath Hospital and the Helen Joseph Hospital.  
This was achieved using the Memorial Symptom Assessment Scale – Short Form (MSAS-SF).  
The objectives of the study to assess the relationship between the symptoms and the 
burden related to the symptoms, with WHO stage, CD4 count results, viral load results, 
performance status as measured by KPS, gender and age were all achieved.  A comparison 
of the symptom prevalence and symptom burden between those patients who were on 
HAART versus those who were not on HAART was not possible, as 98.44% of patients were 
on HAART already.  Too few patients were naive to HAART to make any comparison.  
However, those patients who had had a change in HAART regimen were assessed for 
symptom prevalence and symptom burden instead, in relationship to those who had not 
had a change in HAART.  
The findings show that pain and symptom prevalence is high in this population.  The 
prevalence of pain and symptoms is comparable to other studies conducted in HIV infected 
populations(10,20,22-24), as well as to populations with advanced malignant disease(71).  
Physical and psychological symptoms are all common, with psychological symptoms being 
particularly common, which is also in agreement with the findings of previous 
studies(10,20,22-24).    
The burden of the pain and symptoms experienced by the participants in this study 
population is also high, and again is also comparable to the burden found in other 
studies(10,23-25).  There is high physical, global and psychological distress amongst this 












increased symptom distress for all the MSAS-SF distress subscales (MSAS-GDI, -PHYS, -
PSYCH, and TMSAS) were a KPS score of <100%, WHO stage 2, 3 or 4, and the female 
gender.  The findings also show that patients who report the presence of pain, regardless of 
distress rating, had statistically significant greater psychological distress than patients with 
no pain.   
Viral load results, CD4 count results and age were found to have no significant relationship 
with the three MSAS-SF subscales, which is consistent with the findings from other 
studies(10,14,25).  However on multiple regression analysis a lower latest CD4 count was 
predictive of increased physical distress, but not predictive of any of the other subscales, 
while a previous study found that the latest CD4 was predictive of global distress(24).   
When comparing any previous change in the HAART regimen to symptom prevalence and 
MSAS-PHYS in this study, there was no significant difference found between those patients 
who had changed HAART, compared with those who had not changed HAART.  The length of 
time on HAART was also not associated with symptom prevalence.  However on multiple 
regression analysis, any previous change in HAART was predictive of an increased total 
symptom score (TMSAS), but was not predictive of any of the symptom distress subscales.   
These results show a high symptom prevalence and burden for patients who are taking 
HAART, regardless of CD4 count, viral load, WHO stage, KPS, gender and age, indicating 
significant unmet needs in the patients attending the HIV treatment clinics involved in the 
study.  There are unmet needs for physical symptom control, including nociceptive and 
neuropathic pain control, as well as significant unmet needs for psychological symptom 
control and support.   
 
Recommendations 
These results highlight the palliative care needs of patients with HIV to their health care 
workers at HIV treatment clinics in South Africa, and to HIV clinicians in South Africa in 
general.  The large symptom prevalence and associated high burden of symptoms amongst 
the study population suggest that there is inadequate assessment and management of 












the high prevalence of pain (both nociceptive and neuropathic pain), the feelings of sadness 
and of worry, however all the symptoms experienced by patients deserve assessment and 
management.  For symptoms to be treated effectively, the health care worker would first 
have to recognise that symptoms may be present, and that they should therefore be 
adequately screened for.  A symptom screening tool would assist the clinician in the 
recognition of symptoms.  Several symptom screening tools exist, but the most appropriate 
tool for the particular clinic should be selected, or as in the study by Green et al in Vietnam, 
an appropriate tool can be developed by the clinic themselves(36).  The time required for 
use of the screening tool would need to be short enough for the tool to be realistically 
viable for use in a busy HIV outpatient treatment clinic.  Ideally symptom screening tools 
should be used at each patient clinic visit.  The tool could be used by a nurse when vital 
signs are checked prior to the patient seeing the doctor, with the results available for quick 
reference by the doctor.  Once recognised, symptoms should be effectively and 
appropriately managed.  The symptoms identified by the screening tool should guide the 
completion of a comprehensive and individualised care plan that will be a useful guide on 
each subsequent review of the patient, so as to be able to adequately assess the response 
to treatment.  This requires that the health care worker should have the necessary training 
in symptom management and also in palliative care.  Symptom management and palliative 
care should be seen as part of the regular service rendered to the patient, with the aim of 
improved quality of life for the patient, and so as to encourage, assist and improve HAART 
adherence among patients.  It may be deemed practical to dedicate particular staff in each 
clinic to lead this initiative because training of all staff may be considered impractical, 
however, if all staff are trained in palliative care and conversant with the principles and tools 
used, more patients are likely to benefit from palliative care interventions.    
To be able to effective and appropriately meet these aims, there will need to be increased 
health care worker education in the area of symptom control and palliative care – for 
doctors, nurses, counsellors, social workers, psychologists and allied health professionals.  
This education should occur for the staff at the HIV treatment clinics involved in this study, 
and in the longer term, also for staff at HIV treatment clinics throughout South Africa so that 
a meaningful difference to the lives of South Africans with HIV can be made, particularly for 












nature, as it is the practice of palliative care which advances patient quality of life, not 
necessarily the theory of palliative care – theory must be translated into action.  Palliative 
care principles and management principles should be incorporated into routine HIV patient 
clinic management, to the benefit of the patient.  Green at al write that “for integration to 
occur, palliative care needs to be “routinized” into HIV clinical settings”(36).    Green et al 
also talk of the mentoring process in their study which assisted the clinic staff in becoming 
familiar with the assessment and management of symptoms, both physical and 
psychological symptoms(36).  Green et al found that physicians found increased job 
satisfaction at being able to treat their patients’ symptoms effectively(36).  This finding 
should assist in allaying concerns that the addition of the palliation of symptoms will 
increase the workload of physicians in HIV treatment clinics.  Improved patient outcomes 
and patient satisfaction should improve health care worker job satisfaction and with this 
improved clinician competence could potentially streamline patient management.   
The results of this study conducted in the three HIV treatment clinics described are also 
highly relevant for anyone involved in public health planning in South Africa.  The results 
show a large prevalence of unmet physical and psychological needs.  The literature shows 
that these needs, if unmet, can lead to future virological failure and poor HAART 
adherence(31,37).  It is crucial to do all we can as health care workers to assist patients in 
their adherence to HAART, from humanitarian, medical, social and economic points of view.  
To be able to manage physical symptoms, drug availability will need to be ensured, at 
national, provincial, regional and local levels.  Staff numbers would not need to be increased 
if all health care workers are well trained in palliative care and if protocols are in place for 
the routine implementation of palliative care for all patients.  This requires ongoing work 
and collaboration between palliative care advocates, HIV clinicians and the public health 
planners. 
This study raises questions that will require further research in the South African context.  
As social, financial, food and home circumstances were not enquired about in this study, 
there is a need to relate these factors to the influence they may have on the prevalence and 
burden of the MSAS-SF symptoms and on the biological data.  This should include research 
into the nutritional status of patients and how this relates to symptoms and symptom 












Short Form to assess the quality of social support(10), while Makoae et al included the 
access to a Disability Grant as an marker for financial security(20).  Educational levels and 
employment have been found to impact symptom prevalence and burden elsewhere, 
including rural South Africa, and it would be useful to know the impact of these factors on 
the symptom prevalence and symptom burden of the population group studied(20,22,23).   
Further study into the sites, types, intensity and treatment of specific pains in this 
population group is warranted.  It would also be clinically useful to have more research 
amongst this population group into the relationships between nociceptive and neuropathic 
pain with psychological symptoms such as feeling sad, worrying and feeling irritable.   This 
should therefore also include a more formalised assessment of depression amongst these 
patients.  It would be beneficial to survey HIV physician knowledge and skills in pain and 
symptom management, so as to formally assess and quantify the training needs that have 
been shown to be present from the findings of this study.  This knowledge and skill should 
also be surveyed among nurses so as to assess their specific training needs.   
Other studies have raised the concern that HAART is related to symptom prevalence and 
burden(22,24).  It would be most informative to do longitudinal studies of pain and 
symptoms from the time of diagnosis, throughout all stages of treatment, including 
treatment on HAART, for a significant length of time. The prevalence of HIV in South Africa is 
very high and thus the need for HAART is significant enough to warrant such studies so that 
these and other questions relating to adherence and the quality of life of HIV infected 
people can be better understood.   
The most important recommendation from this study is that palliative care is required by all 
patients with HIV, so that patient outcomes can be improved.  Therefore palliative care 
should be incorporated alongside the current routine HIV care that is presented in HIV 
treatment clinics.  Without the routine palliation of symptoms at the clinic where patients 
receive their primary HIV care patients will continue to needlessly suffer from physical and 
psychological symptoms that do have evidence based and acceptable treatments.   
















(1) Statistics South Africa. Mid-year Population Estimates 2010. 2010 20 July 2010; Statistical 
Release P0302. 
(2) Department of Health. National Antenatal Sentinal HIV and Syphilis Prevalence Survey in 
South Africa, 2009. 2010. 
(3) Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, et al.  
South African national HIV prevalence, incidence, behaviour and communication survey 
2008: 
A turning tide among teenagers? 2009. 
(4) South African National Department of Health. The South African Antiretroviral Treatment 
Guidelines 2010. 2010. 
(5) South African National Department of Health. HIV Treatment Guidelines 2004; 2004. 
(6) Sepulveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health 
Organization's global perspective. J Pain Symptom Manage 2002 Aug;24(2):91-96. 
(7) Lundgren JD, Mocroft A. The impact of antiretroviral therapy on AIDS and survival. J HIV 
Ther 2006 Jun;11(2):36-38. 
(8) Selwyn PA, Rivard M. Overview of Clinical Issues. In: O'Neill JF, Selwyn PA, Schietinger H, 
editors. A Clinical Guide to Supportive and Palliative Care for HIV/AIDS. 2003rd ed.: HRSA; 
2003. p. 5. 
(9) O'Neill JF, Barini-Garcia M. HIV and Palliative Care. In: O'Neill JF, Selwyn PA, Schietinger 
H, editors. A Clinical Guide to Supportive and Palliative Care for HIV/AIDS. 2003rd ed.: HRSA; 
2003. p. 1. 
(10) Vogl D, Rosenfeld B, Breitbart W, Thaler H, Passik S, McDonald M, et al. Symptom 
prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage 1999 
Oct;18(4):253-262. 
(11) Silverberg MJ, Gore ME, French AL, Gandhi M, Glesby MJ, Kovacs A, et al. Prevalence of 
clinical symptoms associated with highly active antiretroviral therapy in the Women's 
Interagency HIV Study. Clin Infect Dis 2004 Sep 1;39(5):717-724. 
(12) Hewitt DJ, McDonald M, Portenoy RK, Rosenfeld B, Passik S, Breitbart W. Pain 
syndromes and etiologies in ambulatory AIDS patients. Pain 1997 Apr;70(2-3):117-123. 
(13) Frich LM, Borgbjerg FM. Pain and pain treatment in AIDS patients: a longitudinal study. 












(14) Willard S, Holzemer WL, Wantland DJ, Cuca YP, Kirksey KM, Portillo CJ, et al. Does 
"asymptomatic" mean without symptoms for those living with HIV infection? AIDS Care 
2009 Mar;21(3):322-328. 
(15) Harding R, Simms V, Krakauer E, Delima L, Downing J, Garanganga E, et al. Quality HIV 
Care to the End of life. Clin Infect Dis 2011 Feb;52(4):553-4; author reply 554. 
(16) Gwyther L. Strenghtening Primary health care. 2011; Personal Communication from Dr 
L Gwyther, CEO HPCA, to Dr Pillay, DOH, 28 January 2011. 
(17) Wakeham K, Harding R, Bamukama-Namakoola D, Levin J, Kissa J, Parkes-Ratanshi R, et 
al. Symptom burden in HIV-infected adults at time of HIV diagnosis in rural Uganda. J Palliat 
Med 2010 Apr;13(4):375-380. 
(18) Fontaine A, Larue F, Lassauniere JM. Physicians' recognition of the symptoms 
experienced by HIV patients: how reliable? J Pain Symptom Manage 1999 Oct;18(4):263-
270. 
(19) Norval DA. Symptoms and sites of pain experienced by AIDS patients. S Afr Med J 2004 
Jun;94(6):450-454. 
(20) Makoae LN, Seboni NM, Molosiwa K, Moleko M, Human S, Sukati NA, et al. The 
symptom experience of people living with HIV/AIDS in Southern Africa. J Assoc Nurses AIDS 
Care 2005 May-Jun;16(3):22-32. 
(21) Shawn ER, Campbell L, Mnguni MB, Defilippi KM, Williams AB. The spectrum of 
symptoms among rural South Africans with HIV infection. J Assoc Nurses AIDS Care 2005 
Nov-Dec;16(6):12-23. 
(22) Peltzer K, Phaswana-Mafuya N. The symptom experience of people living with HIV and 
AIDS in the Eastern Cape, South Africa. BMC Health Serv Res 2008;8:271. 
(23) Harding R, Lampe FC, Norwood S, Date HL, Clucas C, Fisher M, et al. Symptoms are 
highly prevalent among HIV outpatients and associated with poor adherence and 
unprotected sexual intercourse. Sex Transm Infect 2010 Jun 15. 
(24) Harding R, Molloy T, Easterbrook P, Frame K, Higginson IJ. Is antiretroviral therapy 
associated with symptom prevalence and burden? Int J STD AIDS 2006 Jun;17(6):400-405. 
(25) Lee KA, Gay C, Portillo CJ, Coggins T, Davis H, Pullinger CR, et al. Symptom experience in 
HIV-infected adults: a function of demographic and clinical characteristics. J Pain Symptom 
Manage 2009 Dec;38(6):882-893. 
(26) Pappas G, Wolf RC, Morineau G, Harding R. Validity of measures of pain and symptoms 
in HIV/AIDS infected households in resources poor settings: results from the Dominican 
Republic and Cambodia. BMC Palliat Care 2006;5:3. 
(27) Selwyn PA. Why should we care about palliative care for AIDS in the era of antiretroviral 
therapy? Sex Transm Infect 2005 Feb;81(1):2-3. 
(28) Higginson IJ, Donaldson N. Relationship between three palliative care outcome scales. 












(29) Kaasa S, Loge JH. Quality of life in palliative care: principles and practice. Palliat Med 
2003 Jan;17(1):11-20. 
(30) Burgoyne RW, Rourke SB, Behrens DM, Salit IE. Long-term quality-of-life outcomes 
among adults living with HIV in the HAART era: the interplay of changes in clinical factors 
and symptom profile. AIDS Behav 2004 Jun;8(2):151-163. 
(31) Sherr L, Lampe F, Norwood S, Leake Date H, Harding R, Johnson M, et al. Adherence to 
antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care 
2008 Apr;20(4):442-448. 
(32) Bhargava A, Booysen F leR. Healthcare infrastructure and emotional support are 
predictors of CD4 cell counts and quality of life indices of patients on antiretroviral 
treatment in Free State Province, South Africa. AIDS Care 2010 Jan;22(1):1-9. 
(33) Breitbart W, Rosenfeld BD, Passik SD, McDonald MV, Thaler H, Portenoy RK. The 
undertreatment of pain in ambulatory AIDS patients. Pain 1996 May-Jun;65(2-3):243-249. 
(34) Karus D, Raveis VH, Alexander C, Hanna B, Selwyn P, Marconi K, et al. Patient reports of 
symptoms and their treatment at three palliative care projects servicing individuals with 
HIV/AIDS. J Pain Symptom Manage 2005 Nov;30(5):408-417. 
(35) Harding R, Powell RA, Kiyange F, Downing J, Mwangi-Powell F. Provision of Pain- and 
Symptom-Relieving Drugs for HIV/AIDS in Sub-Saharan Africa. J Pain Symptom Manage 2010 
9;40(3):405-415. 
(36) Green K, Tuan T, Hoang TV, Trang NN, Ha NT, Hung ND. Integrating palliative care into 
HIV outpatient clinical settings: preliminary findings from an intervention study in Vietnam. J 
Pain Symptom Manage 2010 Jul;40(1):31-34. 
(37) Lampe FC, Harding R, Smith CJ, Phillips AN, Johnson M, Sherr L. Physical and 
Psychological Symptoms and Risk of Virologic Rebound Among Patients With Virologic 
Suppression on Antiretroviral Therapy. J Acquir Immune Defic Syndr 2010 Feb 10. 
(38) Rodkjaer L, Laursen T, Balle N, Sodemann M. Depression in patients with HIV is under-
diagnosed: a cross-sectional study in Denmark. HIV Med 2010 Jan;11(1):46-53. 
(39) Dorland's Illustrated Medical Dictionary. 31st Edition ed. Philadelphia: Saunders, 
Elsevier; 2007. 
(40) Bowie C, Kalilane L, Cleary P. The pattern of symptoms in patients receiving home based 
care in Bangwe, Malawi : a descriptive study. BMC Palliat Care 2006;5:1. 
(41) IASP Task Force on Taxonomy (1994). Classification of Chronic Pain. 1994. 
(42) Twycross R, Wilcock A. Symptom management in advanced cancer. 3rd ed. Oxford: 
Radcliff Medical Press; 2006. 
(43) Breitbart W, McDonald MV, Rosenfeld B, Passik SD, Hewitt D, Thaler H, et al. Pain in 












(44) Rosenfeld B, Breitbart W, McDonald MV, Passik SD, Thaler H, Portenoy RK. Pain in
ambulatory AIDS patients. II: Impact of pain on psychological functioning and quality of life.
Pain 1996 Dec;68(2-3):323-328.
(45) Richardson JL, Heikes B, Karim R, Weber K, Anastos K, Young M. Experience of pain
among women with advanced HIV disease. AIDS Patient Care STDS 2009 Jul;23(7):503-511.
(46) Del Borgo C, Izzi I, Chiarotti F, Del Forno A, Moscati AM, Cornacchione E, et al.
Multidimensional aspects of pain in HIV-infected individuals. AIDS Patient Care STDS 2001
Feb;15(2):95-102.
(47) Parker R. Personal communication regarding an ongoing and currently unpublished
study on pain in women with HIV in Cape Town. 2011.
(48) Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, et al. Continued
high prevalence and adverse clinical impact of human immunodeficiency virus-associated
sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.
Arch Neurol 2010 May;67(5):552-558.
(49) Selwyn PA, Rivard M, Kappell D, Goeren B, LaFosse H, Schwartz C, et al. Palliative care
for AIDS at a large urban teaching hospital: program description and preliminary outcomes. J 
Palliat Med 2003 Jun;6(3):461-474.
(50) Harding R, Karus D, Easterbrook P, Raveis VH, Higginson IJ, Marconi K. Does palliative 
care improve outcomes for patients with HIV/AIDS? A systematic review of the evidence. 
Sex Transm Infect 2005 Feb;81(1):5-14.
(51) Holzemer WL. HIV and AIDS: The Symptom Experience. Am J Nurs 2002 Apr.;102(4):pp.
48-52.
(52) Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, et al. 
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive 
women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001 Mar 
21;285(11):1466-1474.
(53) Sherr L, Harding R, Lampe F, Johnson M, Anderson J, Zetler S, et al. Clinical and
behavioural aspects of aging with HIV infection. Psychol Health Med 2009 May;14(3):273-
279.
(54) Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M. Effect of antiretroviral therapy
on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a
community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch
Intern Med 2000 Apr 24;160(8):1134-1140.
(55) Senyimba C, Mwebesa E, Kennelly S, Frame K, Harding R. A theme issue by, for, and
about Africa: palliative care and antiretroviral treatment can be integrated. BMJ 2005 Oct
1;331(7519):778-779.
(56) Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced
cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain











(57) Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care. BMJ
2005 Apr 30;330(7498):1007-1011.
(58) Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the
end of life. JAMA 2003 May 14;289(18):2387-2392.
(59) Gomes B, Harding R, Foley KM, Higginson IJ. Optimal approaches to the health
economics of palliative care: report of an international think tank. J Pain Symptom Manage
2009 Jul;38(1):4-10.
(60) Harding R. Palliative care in resource-poor settings: fallacies and misapprehensions. J
Pain Symptom Manage 2008 Nov;36(5):515-517.
(61) Higginson IJ, Foley KM. Palliative care: no longer a luxury but a necessity? J Pain
Symptom Manage 2009 Jul;38(1):1-3.
(62) Krakauer EL. Just palliative care: responding responsibly to the suffering of the poor. J 
Pain Symptom Manage 2008 Nov;36(5):505-512.
(63) Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, et al. The 
Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom 
prevalence, characteristics and distress. Eur J Cancer 1994;30A(9):1326-1336.
(64) Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT. The memorial symptom 
assessment scale short form (MSAS-SF). Cancer 2000 Sep 1;89(5):1162-1171.
(65) Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An
examination of its reliability and validity in a research setting. Cancer 1984 May 
1;53(9):2002-2007.
(66) Schwartz CE, Merriman MP, Reed G, Byock I. Evaluation of the Missoula-VITAS Quality 
of Life Index--revised: research tool or clinical tool? J Palliat Med 2005 Feb;8(1):121-135.
(67) Mphahlele N, Mitchell D, Kamerman P. Validation of the Wisconsin Brief Pain
Questionnaire in a multilingual South African population. J Pain Symptom Manage 2008
Oct;36(4):396-412.
(68) Holzemer WL, Hudson A, Kirksey KM, Hamilton MJ, Bakken S. The revised Sign and
Symptom Check-List for HIV (SSC-HIVrev). J Assoc Nurses AIDS Care 2001 Sep-Oct;12(5):60-
70.
(69) Department of Health.
Guidelines for Good Practice in the Conduct of Clinical Trials with Human Participants in
South Africa. 2006.
(70) NHLS. Chemical Pathology Reference Values. 2010.
(71) Harding R, Selman L, Agupio G, Dinat N, Downing J, Gwyther L, et al. The prevalence and
burden of symptoms amongst cancer patients attending palliative care in two African












(72) Lampe FC, Harding R, Smith CJ, Phillips AN, Johnson M, Sherr L. Physical and 
psychological symptoms and risk of virologic rebound among patients with virologic 
suppression on antiretroviral therapy. J Acquir Immune Defic Syndr 2010 Aug 15;54(5):500-
505. 
(73) Sherr L, Lampe F, Fisher M, Arthur G, Anderson J, Zetler S, et al. Suicidal ideation in UK 
HIV clinic attenders. AIDS 2008 Aug 20;22(13):1651-1658. 
(74) Rossiter D, Blockman M. editors. South African Medicines Formulary. Ninth Edition ed. 
Cape Town: Health and Medical Publishing Group; 2010. 
(75) Charles C, Gafni A, Whelan T. How to improve communication between doctors and 
patients. Learning more about the decision making context is important. BMJ 2000 May 
6;320(7244):1220-1221. 
(76) Gwyther L, Merriman A, Mpanga Sebuyira L, Schietinger H. editors. A Clinical Guide to 
Supportive and Palliative Care for HIV/AIDS for Sub-Saharan Africa. 2006 ed.; 2006. 
(77) Evans S, Ferrando S, Sewell M, Goggin K, Fishman B, Rabkin J. Pain and depression in 
HIV illness. Psychosomatics 1998 Nov-Dec;39(6):528-535. 
(78) Wilson TE, Jean-Louis G, Schwartz R, Golub ET, Cohen MH, Maki P, et al. HIV infection 
and women's sexual functioning. J Acquir Immune Defic Syndr 2010 Aug 1;54(4):360-367. 
(79) Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in 
advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory 
nutritional index. Support Care Cancer 2003 Jan;11(1):60-62. 
(80) Fuhrman MP. The albumin-nutrition connection: separating myth from fact. Nutrition 
2002 Feb;18(2):199-200. 
(81) Gwyther L, Merriman A, Mpanga Sebuyira L, Schietinger H editors. A Clinical Guide to 
Supportive and Palliative Care for HIV/AIDS in Sub-Saharan Africa. 2006th ed.; 2006. 
(82) Gwyther L, Adams V, Wilson D, Mandwa DA. Respiratory Symptoms. In: Gwyther L, 
Merriman A, Mpanga Sebuyira L, Schietinger H, editors. A Clinical Guide to Supportive and 
Palliative Care for HIV/AIDs in Sub-Saharan Africa. 2006 Edition ed.; 2006. 



























Participant Information Form 
Hello, my name is Dr Lindsay Farrant.    
I am a doctor doing the following study, with the help of the nurse who is speaking to you.  You 
are invited to take part in this study: 
 
To survey the prevalence and burden of pain and symptoms amongst HIV 
positive patients attending HIV treatment clinics 
This study wants to find out how common some problems are for people who are HIV positive 
in South Africa.  This means that we ask each person who takes part in the study to answer 
some questions that will tell us what they feel or what problems they have.   This way we can 
understand how common these problems are amongst people who are HIV positive in 
Johannesburg, South Africa.  This should help doctors and nurses to better understand and 
treat people living with HIV in Johannesburg.  This study is part of my studies for a degree and 
has been supported by the Research Ethics Committees of the University of Cape Town and the 
University of the Witwatersrand. It is being supported by the Gauteng Centre of Excellence for 
Palliative Care which is part of the Department of Medicine of the University of the 
Witwatersrand, as a non-profit research entity.  The study is being supported by this Centre 
because it wants to improve our understanding of symptoms and pain among patients who are 
HIV positive. 
You are free to choose if you want to take part in this study.  The study is being conducted at 
this clinic where you usually get your treatment.  Your treatment at this clinic will remain the 
same, whatever you decide. You may stop answering the questions at any time or choose not 
to answer some questions and you may withdraw from the study at any time.  The doctors and 
nurses who are treating you in this clinic know about this study and accept it.  They will receive 
the results of this study when it is completed.  Once this study is finished, the results will be put 
on posters on the walls of this clinic, but will not include any of your details or your name.  Your 
name and details will not be used or seen by anyone other than the person doing this study – 
the researcher’s name is at the bottom of this page.  All papers with your name and details will 
be stored carefully to ensure that everything is confidential and anonymous.  Your name will 
not appear anywhere on any report that comes out of the results in this study.   
If you agree to take part in this study, you are agreeing to a single interview in English, Sesotho 
or isiZulu, and to the interviewer copying down information from your file.  This should all take 
around about 30 - 40 minutes.  There are no direct benefits – you will not receive any money or 
gift – but this study will help us to understand important problems that you experience.  There 











medication, but we will check your file for your results.  Should we find any problems that have 
not been treated we will refer you to a doctor.   
If you would like to, you can telephone the person doing this study for more detailed 
information, at any time, on 011 933 4916.  The researcher’s name is Dr Lindsay Farrant. 
Thank you very much. 
RESEARCHER Dr Lindsay Farrant 
Wits Palliative Care, Chris Hani Baragwanath Hospital, Johannesburg 
PO Box 212, Pimville, 1808 
Tel:  27 11 933 4916  Fax:  27 11 933 1701 
Contact details: University of Cape Town Research Ethics Committee 
Mrs Lameez Emjedi
Faculty of Health Sciences
Research Ethics Committee
E 46-26 Old Main Building, Groote Schuur Hospital, Observatory ,7925
Tel: 27 21 4066492 Fax: 27 21 4066411





University of the Witwatersrand













Participant Consent Form: 
Dear Patient, 
You are invited to take part in this study: 
 
To survey the prevalence and burden of pain and symptoms amongst HIV 
positive patients attending HIV treatment clinics 
In this study I will answer questions about the problems I face in my daily life, especially the last 
week.   I understand it will take about 15 minutes. 
I am freely taking part in this study.  I am here to see the doctor at the clinic where I normally 
get my treatment.   
I understand that the person asking me the questions will use my clinic file but that all 
information will be kept strictly confidential and anonymous – no one else but the person 
asking the questions and the person doing the study will see the information.  I understand that 
I may stop answering any questions at any time. 
I have been given a telephone contact number for the person doing this study. 
I understand that whatever I decide, my treatment at this clinic will remain the same. 
I understand that once this study is finished, the results, without any names or patient details, 
will be put on posters on the walls of this clinic.  I can also telephone the person doing this 
study for more detailed information on the results. 
I understand this and the patient information sheet that I have received and agree that I have 
had sufficient time to think about this and ask any questions I have and to decide on my 
participation in this study.  I agree to my file being used for the information needed and to 
answer the questionnaire.  I now freely agree to take part in this study. 
 
Signed / or Thumbprint (where unable to sign):_______________________________________ 
Name and Surname:_________________________________________________________ 
Date: _____________________________Place:___________________________________ 
Witness Signature______________________    













Participant Data Sheet: 
Date:______________________ Study Number:________________ 
Age at last birthday:_____________________ Gender:  Male________Female______________ 
Self-determined Ethnicity:  Black_____Coloured___White_____Indian_______Other___ 
Latest CD 4 Count:______________________ (date:____________) If not available: _________ 
Latest Viral Load:________________________(date:______________) If not available: _______ 
Latest Albumin level: _____________________(date:______________) If not available: ______ 
Initial CD 4 count before starting HAART______________(date:____________) If not avail:____ 
Initial Viral Load before starting HAART_______________(date:____________) If not avail:____ 
WHO staging: ________________________    
HIV – Related diagnoses: 
______________________________________________________________________________ 
Diagnoses unrelated to HIV: _______________________________________________________ 
Is patient on HAART?  Yes________No________ If YES, the date of starting________________ 
If YES, the names of the drugs the patient is currently taking 
________________________________________________________________________ 
Has any change of HAART occurred?   Yes___________No_______________ 
If YES, Date of change ___________& previous regimen________________________________ 
And reason for change___________________________________________________________ 
Additional information not in patient file: 
Current Karnofsky Performance Status (KPS):______________(According to attached KPS Scale) 
After the MSAS-SF, if the patient is on ARV’s, ask the patient the following question: 
Do you think that any of your symptoms are because of your ARV’s:  YES______ or NO______ 















 Karnofsky Performance Scale  
 
(For use with persons ages > 17 years)  
 
100% = Normal; no complaints, no evidence of disease  
90% = Able to carry on normal activity; minor signs or symptoms of disease  
80% = Normal activity with effort, some signs or symptoms of disease  
70% = Cares for self; unable to carry on normal activity or to do active work  
60% = Requires occasional assistance, but is able to care for most of own needs  
50% = Requires considerable assistance and frequent medical care  
40% = Disabled, requires special care and assistance  
30% = Severely disabled, hospitalization is indicated although death is not imminent  
20% = Hospitalization necessary, very sick, active supportive treatment necessary  
10% = Moribund, fatal processes progressing rapidly  
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 Falmouth Building, Entrance 5, Level 2, Office 2.20 
 
Head of Division: Prof D A Hellenberg 
Full-time staff members: Dr G Bresick, Dr E De Vries, Dr E Gwyther,  
Dr M Namane, Dr  B Schweitzer 
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I have worked with Dr Farrant regarding the corrections to her dissertation following the 
recommendations from the external examiners and dissertations committee. 
I am satisfied that she has addressed the external examiners’ comments adequately. She 
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         Valdora House 
         Flat 6 
         31 Grove Avenue 
         Claremont 
         7700 
         20 October 2011 
Professor Blockmann 
Dean of Postgraduate Studies 
Faculty of Health Sciences 




Dear Professor Blockmann 
 
Re:  Submission of corrections to the dissertation towards MPhil Pall Med  
by Dr Lindsay Farrant, FRRLIN002 
 
This letter serves to confirm and describe the corrections I have made to the Dissertation 
that I submitted to your office on 1 April 2011, according to the suggestions of the 
Examiners’ reports.   
 
The data of the Results chapter were re-arranged according to the Examiner’s requirements.  
All tables, graphs and figures were named, numbered and indexed as requested.  The 
demographic data was retained at the start of the Results chapter as this follows University 
practice, as discussed with my supervisor.  The table of ‘Demographic Information’ was 
moved to the start of the demographics section of this chapter, as advised, and is now 
labeled Table 1.  This table was also adjusted as advised, to include distinct lines for the 
ranges for Age, Initial CD4 count and Latest CD4 count.  All the minor errors identified by the 
first examiner in the Results chapter were corrected.  Graph 11 on p56 was changed so as 











The Examiner’s “concern regarding equating high prevalence of symptoms with inadequate 
assessment and management by clinicians” was specifically addressed by rewording each
such instance to indicate that this could only be suggested but could not be concluded. The 
Discussion chapter was further adapted to make it more focused, with clearer flow of
thought and with less repetition. The concern of the Examiner regarding “body-fat
distribution changes” and “I don’t look like myself” is discussed in the Discussion chapter as
being related and they were not analysed as one concept. The Introduction chapter was 
minimally adapted, to remove unnecessary repetition. The suggestion by the Examiner to
shorten the Introductory and Discussion chapters was noted not to be essential and thus
the chapters were not shortened greatly, apart from the changes noted already, as my 
supervisor and I considered these changes to be sufficient and also appropriate in retaining
the integrity of the dissertation. 
The typographical and grammatical errors noted by the External Examiner have all been
corrected. The specific questions relating to the Literature Review chapter and
Methodology chapter have now been clarified in the text.  In the Discussion chapter, the 
Constitutional Symptom Subscale was reported on because it had been used for the first
time and it was felt that the fact that it was found to be an unreliable scale was in itself
important to report. 
The corrected version of the dissertation has been discussed with my supervisor and I am 
now ready to submit this to the Postgraduate Office.
Yours sincerely, 
Lindsay Farrant 
